TRANSLATIONAL GENOMICS RESEARCH INSTITUTE: Form 990, tax year 2011

View the entire original 990 at ProPublica ↗

Organization: TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (EIN 75-3065445)
Tax period: 2011-12-01 to 2012-11-30
Filed: 2013-10-24
IRS object ID: 201332979349300713
Schema version: 2011v1.5
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule D
Schedule F
Schedule J
Schedule L
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Timestamp	2013-10-24T10:21:49-05:00	Timestamp
Tax Period End Date	2012-11-30	TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	ERNST & YOUNG US LLP	BusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

Field	Value	IRS element (for citing)
Address Line1	TWO NORTH CENTRAL AVENUE STE 2300	AddressLine1
City	PHOENIX	City
State	AZ	State
ZIP Code	85004	ZIPCode

Field	Value	IRS element (for citing)
Return Type	990	ReturnType
Tax Period Begin Date	2011-12-01	TaxPeriodBeginDate

Filer Filer

Field	Value	IRS element (for citing)
EIN	753065445	EIN

Name Name

Field	Value	IRS element (for citing)
Business Name Line1	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	BusinessNameLine1

Field	Value	IRS element (for citing)
In Care Of Name	% CHARLES K COLESON	InCareOfName
Name Control	TRAN	NameControl
Phone	6023438423	Phone

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	445 N 5TH STREET SUITE 600	AddressLine1
City	PHOENIX	City
State	AZ	State
ZIP Code	85004	ZIPCode

Officer Officer

Field	Value	IRS element (for citing)
Name	CHUCK COLESON	Name
Title	CFO	Title
Date Signed	2013-10-14	DateSigned

Preparer Preparer

Field	Value	IRS element (for citing)
Phone	6023223000	Phone

Field	Value	IRS element (for citing)
Tax Year	2011	TaxYear
Build TS	2016-02-24 21:20:13Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Name Of Principal Officer Person	JEFFREY TRENT PHD	NameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

Field	Value	IRS element (for citing)
Address Line1	SAME AS C ABOVE	AddressLine1
City	PHOENIX	City
State	AZ	State
ZIP Code	85004	ZIPCode

Field	Value	IRS element (for citing)
Gross Receipts	48492051	GrossReceipts
Group Return For Affiliates	false	GroupReturnForAffiliates
Organization501c3	X	Organization501c3
Web Site	WWW.TGEN.ORG	WebSite
Type Of Organization Corporation	X	TypeOfOrganizationCorporation
Year Formation	2002	YearFormation
State Legal Domicile	AZ	StateLegalDomicile
Activity Or Mission Description	SEE SCHEDULE O	ActivityOrMissionDescription
Nbr Voting Members Governing Body	15	NbrVotingMembersGoverningBody
Nbr Independent Voting Members	13	NbrIndependentVotingMembers
Total Nbr Employees	402	TotalNbrEmployees
Total Nbr Volunteers	60	TotalNbrVolunteers
Total Gross UBI	0	TotalGrossUBI
Net Unrelated Business Txbl Income	0	NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year	39499881	ContributionsGrantsPriorYear
Contributions Grants Current Year	27781232	ContributionsGrantsCurrentYear
Program Service Revenue Prior Year	20855027	ProgramServiceRevenuePriorYear
Program Service Revenue CY	19840214	ProgramServiceRevenueCY
Investment Income Prior Year	328555	InvestmentIncomePriorYear
Investment Income Current Year	20014	InvestmentIncomeCurrentYear
Other Revenue Prior Year	138641	OtherRevenuePriorYear
Other Revenue Current Year	850591	OtherRevenueCurrentYear
Total Revenue Prior Year	60822104	TotalRevenuePriorYear
Total Revenue Current Year	48492051	TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year	0	GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY	0	GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year	0	BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY	0	BenefitsPaidToMembersCY
Salaries Etc Prior Year	28036987	SalariesEtcPriorYear
Salaries Etc Current Year	26595987	SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year	0	TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY	0	TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year	0	TotalFundrsngExpCurrentYear
Other Expense Prior Year	45136527	OtherExpensePriorYear
Other Expenses Current Year	31036585	OtherExpensesCurrentYear
Total Expenses Prior Year	73173514	TotalExpensesPriorYear
Total Expenses Current Year	57632572	TotalExpensesCurrentYear
Revenues Less Expenses Prior Year	-12351410	RevenuesLessExpensesPriorYear
Revenues Less Expenses CY	-9140521	RevenuesLessExpensesCY
Total Assets BOY	50603221	TotalAssetsBOY
Total Assets EOY	42514714	TotalAssetsEOY
Total Liabilities BOY	17805103	TotalLiabilitiesBOY
Total Liabilities EOY	18198184	TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY	32798118	NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY	24316530	NetAssetsOrFundBalancesEOY
Info In Schedule O Part III	X	InfoInScheduleOPartIII
Mission Description	SEE SCHEDULE O	MissionDescription
Significant New Program Services	false	SignificantNewProgramServices
Significant Change	false	SignificantChange
Expense	5908534	Expense
Grants	0	Grants
Revenue	344531	Revenue
Description	CLINICAL TRIALS - SEE SCHEDULE O.	Description

Activity2 Activity2

Field	Value	IRS element (for citing)
Expense	5343208	Expense
Grants	0	Grants
Revenue	436538	Revenue
Description	CANCER AND CELL BIOLOGY DIVISION - SEE SCHEDULE O.	Description

Activity3 Activity3

Field	Value	IRS element (for citing)
Expense	8508617	Expense
Grants	0	Grants
Revenue	1502155	Revenue
Description	GENOTYPING TECHNOLOGY CENTER - SEE SCHEDULE O.	Description

Field	Value	IRS element (for citing)
Total Of Other Program Service Exp	14779438	TotalOfOtherProgramServiceExp
Total Of Other Program Service Grnt	0	TotalOfOtherProgramServiceGrnt
Total Of Other Program Service Rev	18407581	TotalOfOtherProgramServiceRev
Total Program Service Expense	34539797	TotalProgramServiceExpense
Described In501 C3	true	DescribedIn501C3
Schedule B Required	true	ScheduleBRequired
Political Activities	false	PoliticalActivities
Lobbying Activities	false	LobbyingActivities
Subject To Proxy Tax	false	SubjectToProxyTax
Donor Advised Funds	false	DonorAdvisedFunds
Conservation Easements	false	ConservationEasements
Collections Of Art	false	CollectionsOfArt
Credit Counseling	false	CreditCounseling
Term Or Permanent Endowments	true	TermOrPermanentEndowments
Report Land Bldg Equip	true	ReportLandBldgEquip
Report Invest Oth Securities	false	ReportInvestOthSecurities
Report Prog Rel Invest	false	ReportProgRelInvest
Report Other Assets	false	ReportOtherAssets
Report Other Liabilities	true	ReportOtherLiabilities
Report Fin48 Footnote	true	ReportFin48Footnote
Independent Audit Financial Stmt	false	IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt	false	ConsolidatedAuditFinancialStmt
School	false	School
Foreign Office	false	ForeignOffice
Foreign Activities	true	ForeignActivities
More Than5000 K To Organizations	false	MoreThan5000KToOrganizations
More Than5000 K To Individuals	false	MoreThan5000KToIndividuals
Professional Fundraising	false	ProfessionalFundraising
Fundraising Activities	false	FundraisingActivities
Gaming	false	Gaming
Hospital	false	Hospital
Grants To Organizations	false	GrantsToOrganizations
Grants To Individuals	false	GrantsToIndividuals
Schedule J Required	true	ScheduleJRequired
Tax Exempt Bonds	false	TaxExemptBonds
Excess Benefit Transaction	false	ExcessBenefitTransaction
Prior Excess Benefit Transaction	false	PriorExcessBenefitTransaction
Loan To Officer Or DQP	false	LoanToOfficerOrDQP
Grant To Related Person	false	GrantToRelatedPerson
Bsnss Rltnshp With Organization	false	BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member	false	BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp	true	OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions	true	DeductibleNonCashContributions
Deductible Contributions Of Art	false	DeductibleContributionsOfArt
Terminated	false	Terminated
Partial Liquidation	false	PartialLiquidation
Disregarded Entity	true	DisregardedEntity
Related Entity	true	RelatedEntity
Related Org Controlled Entity	true	RelatedOrgControlledEntity
Transaction Related Entity	true	TransactionRelatedEntity
Transfers To Exempt Non Chrtbl Org	false	TransfersToExemptNonChrtblOrg
Activities Conducted Partnership	false	ActivitiesConductedPartnership
Schedule O Required	true	ScheduleORequired
Number Forms Transmitted With1096	47	NumberFormsTransmittedWith1096
Number W2 G Included	0	NumberW2GIncluded
Compliance With Backup Witholding	true	ComplianceWithBackupWitholding
Number Of Employees	402	NumberOfEmployees
Employment Tax Returns Filed	true	EmploymentTaxReturnsFiled
Unrelated Business Income	false	UnrelatedBusinessIncome
Foreign Financial Account	true	ForeignFinancialAccount
Name Of Foreign Country	LU	NameOfForeignCountry
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTrans
Taxable Party Notification	false	TaxablePartyNotification
Non Deductible Contributions	false	NonDeductibleContributions
Quid Pro Quo Contributions	false	QuidProQuoContributions
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOf
Funds To Pay Premiums	false	FundsToPayPremiums
Premiums Paid	false	PremiumsPaid
Indoor Tanning Services	false	IndoorTanningServices
Info In Schedule O Part VI	X	InfoInScheduleOPartVI
Nbr Voting Governing Body Members	15	NbrVotingGoverningBodyMembers
Number Independent Voting Members	13	NumberIndependentVotingMembers
Family Or Business Relationship	true	FamilyOrBusinessRelationship
Delegation Of Management Duties	false	DelegationOfManagementDuties
Changes To Organizing Docs	true	ChangesToOrganizingDocs
Material Diversion Or Misuse	false	MaterialDiversionOrMisuse
Members Or Stockholders	true	MembersOrStockholders
Election Of Board Members	true	ElectionOfBoardMembers
Decisions Subject To Approval	true	DecisionsSubjectToApproval
Minutes Of Governing Body	true	MinutesOfGoverningBody
Minutes Of Committees	true	MinutesOfCommittees
Officer Mailing Address	false	OfficerMailingAddress
Local Chapters	false	LocalChapters
Form990 Provided To Governing Body	true	Form990ProvidedToGoverningBody
Conflict Of Interest Policy	true	ConflictOfInterestPolicy
Annual Disclosure Covered Persons	true	AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement	true	RegularMonitoringEnforcement
Whistleblower Policy	true	WhistleblowerPolicy
Document Retention Policy	true	DocumentRetentionPolicy
Compensation Process CEO	true	CompensationProcessCEO
Compensation Process Other	true	CompensationProcessOther
Investment In Joint Venture	false	InvestmentInJointVenture
States Where Copy Of Return Is Filed	AZ	StatesWhereCopyOfReturnIsFiled
Upon Request	X	UponRequest

The Books Are In Care Of TheBooksAreInCareOf

Field	Value	IRS element (for citing)
Name Person	CHARLES K COLESON	NamePerson
Telephone Number	6023438599	TelephoneNumber

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	445 N 5TH STREET SUITE 600	AddressLine1
City	PHOENIX	City
State	AZ	State
ZIP Code	85004	ZIPCode

Form990 Part VII Section A Form990PartVIISectionA (32 entries)

TitleTitle	Average Hours Per WeekAverageHoursPerWeek	Individual Trustee Or DirectorIndividualTrusteeOrDirector	Reportable Comp From OrganizationReportableCompFromOrganization	Reportable Comp From Related OrgsReportableCompFromRelatedOrgs	Other CompensationOtherCompensation	OfficerOfficer	Key EmployeeKeyEmployee	Highest Compensated EmployeeHighestCompensatedEmployee	FormerFormer
JERRY BISGROVE
BOARD MEMBER	1.0	X	0	0	0
GOVERNOR JAN BREWER
BOARD MEMBER	1.0	X	0	0	0
ROBERT BULLA
BOARD MEMBER	1.0	X	0	0	0
JOSE CARDENAS
BOARD MEMBER	1.0	X	0	0	0
BENNETT DORRANCE
BOARD MEMBER / SECRETARY	1.0	X	0	0	0	X
PETER S FINE
BOARD MEMBER	1.0	X	0	0	0
BERT GETZ
BOARD MEMBER	1.0	X	0	0	0
DAVID GULLEN MD
BOARD MEMBER	1.0	X	0	0	0
JEFFREY MOORAD
BOARD MEMBER	1.0	X	0	0	0
T LON OWEN PHD
BOARD MEMBER	1.0	X	0	0	0
CINDY PARSEGHIAN
BOARD MEMBER / TREASURER	1.0	X	0	0	0	X
WILLIAM J POST
BOARD MEMBER / CHAIRMAN	1.0	X	0	0	0	X
RICHARD SILVERMAN
BOARD MEMBER	1.0	X	0	0	0
THE HONORABLE GREG STANTON
BOARD MEMBER	1.0	X	0	0	0
JEFFREY TRENT
BM / PRES / SCIENCE DIRECTOR	39.0	X		1085392	455479	X
JOHN KENNEDY
BOARD MEMBER (THRU 3/2012)	1.0	X	0	0	0
DAVID VAN ANDEL
BOARD MEMBER (THRU 3/2012)	1.0	X	0	0	0
TERESA BURLESON
CHIEF OPERATING OFFICER	39.0		440722	0	16059	X
DANIEL VON HOFF
EXECUTIVE VICE PRESIDENT	40.0		684393	0	15717	X
ELIZABETH MONTEMAYOR
CHIEF FINANCIAL OFFICER	40.0		244212	0	20350	X
SPYRO MOUSSES
VICE PRESIDENT	40.0		305359	0	18455		X
MICHAEL BERENS
DEPUTY DIRECTOR OF RESEARCH	40.0		316743	0	16630		X
DAVID DUGGAN
ASSOCIATE PROFESSOR	40.0		258844	0	20488		X
JAMES HARRIS
VP BUSINESS DEVELOPMENT	40.0		209984	0	21657		X
EDWARD SUH
CHIEF INFORMATION OFFICER	40.0		275250	0	18118		X
DAVID CRAIG
DEPUTY DIRECTOR INFO SCIENCES	40.0		157812		54159		X
JOHN CARPTEN
DEPUTY DIRECTOR OF SCIENCES	40.0		242137	0	60462			X
STEPHANIE MCRAE
GENERAL COUNSEL	40.0		283646	0	10442			X
STEPHEN GATELY
TD2 PRESIDENT / SCIENTIFIC DIR	40.0		247019	0	5667			X
JOHANNA DISTEFANO
PROFESSOR	40.0		224193	0	11867			X
GALEN PERRY
VP MARKETING/COMMUNICATIONS	40.0		200680		16871			X
JEFFREY NIEVES
DEPUTY DIRECTOR (THRU 11/2011)	40.0		297766	0	13163				X

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	4388760	TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs	1085392	TotalReportableCompFrmRltdOrgs
Total Other Compensation	775584	TotalOtherCompensation
Number Individuals GT100 K	62	NumberIndividualsGT100K
Formers Listed	true	FormersListed
Total Comp GT150 K	true	TotalCompGT150K
Compensation From Other Sources	false	CompensationFromOtherSources

Contractor Compensation ContractorCompensation (5 entries)

Address Line1AddressOfContractor/AddressForeign/AddressLine1	CityAddressOfContractor/AddressForeign/City	Province Or StateAddressOfContractor/AddressForeign/ProvinceOrState	CountryAddressOfContractor/AddressForeign/Country	Postal CodeAddressOfContractor/AddressForeign/PostalCode	Description Of ServicesDescriptionOfServices	CompensationCompensation	Address Line1AddressOfContractor/AddressUS/AddressLine1	CityAddressOfContractor/AddressUS/City	StateAddressOfContractor/AddressUS/State	ZIP CodeAddressOfContractor/AddressUS/ZIPCode
PERSISTENT SYSTEMS LTD
402E SENAPATI BAPAT RD	PUNE	PUNE	IN	411 016	SOFTWARE DEVELOPMENT	289643
JULIE BERNARD
					LEGAL SERVICES	226621	11076 MAPLE ROAD	LAFAYETTE	CO	80026
ERNST YOUNG LLP
					AUDIT SERVICES	204401	DEPT 6793	LOS ANGELES	CA	90084
PRICEWATERHOUSECOOPERS LLP
					CONSULTING SERVICES	199250	PO BOX 514038	LOS ANGELES	CA	90051
FIRSTSTRATEGIC
					CONSULTING SERVICES	184877	300 W CLARENDON AVE STE 460	PHOENIX	AZ	85013

Field	Value	IRS element (for citing)
Number Of Contractors GT100 K	9	NumberOfContractorsGT100K
Related Organizations	8000000	RelatedOrganizations
Government Grants	12998097	GovernmentGrants
All Other Contributions	6783135	AllOtherContributions
Noncash Contributions	998003	NoncashContributions
Total Contributions	27781232	TotalContributions

Program Service Revenue ProgramServiceRevenue

Field	Value	IRS element (for citing)
Description	RESEARCH CONTRACTS	Description
Business Code	541700	BusinessCode
Total Revenue Column	19840214	TotalRevenueColumn
Related Or Exempt Function Income	19840214	RelatedOrExemptFunctionIncome

Field	Value	IRS element (for citing)
Total Program Service Revenue	19840214	TotalProgramServiceRevenue

Investment Income InvestmentIncome

Field	Value	IRS element (for citing)
Total Revenue Column	20014	TotalRevenueColumn
Exclusion	$20,014	ExclusionAmount

Income From Invest Bond Proceeds IncomeFromInvestBondProceeds

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Royalties Revenue RoyaltiesRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Gain Or Loss Investments NetGainOrLossInvestments

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Income From Gaming NetIncomeFromGaming

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Income Or Loss NetIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Other Revenue Misc OtherRevenueMisc

Field	Value	IRS element (for citing)
Description	ALL OTHER REVENUE	Description
Business Code	900099	BusinessCode
Total Revenue Column	850591	TotalRevenueColumn
Related Or Exempt Function Income	850591	RelatedOrExemptFunctionIncome

Field	Value	IRS element (for citing)
Total Other Revenue	850591	TotalOtherRevenue

Total Revenue TotalRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	48492051	TotalRevenueColumn
Related Or Exempt Function Income	20690805	RelatedOrExemptFunctionIncome
Unrelated Business Revenue	0	UnrelatedBusinessRevenue
Exclusion	$20,014	ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

Field	Value	IRS element (for citing)
Total	0	Total

Grants To Domestic Individuals GrantsToDomesticIndividuals

Field	Value	IRS element (for citing)
Total	0	Total

Foreign Grants ForeignGrants

Field	Value	IRS element (for citing)
Total	0	Total

Benefits To Members BenefitsToMembers

Field	Value	IRS element (for citing)
Total	0	Total

Comp Current Officers Directors CompCurrentOfficersDirectors

Field	Value	IRS element (for citing)
Total	4087276	Total
Program Services	1542451	ProgramServices
Management And General	2544825	ManagementAndGeneral

Comp Disqual Persons CompDisqualPersons

Field	Value	IRS element (for citing)
Total	0	Total

Other Salaries And Wages OtherSalariesAndWages

Field	Value	IRS element (for citing)
Total	18586777	Total
Program Services	9341094	ProgramServices
Management And General	9245683	ManagementAndGeneral

Pension Plan Contributions PensionPlanContributions

Field	Value	IRS element (for citing)
Total	672881	Total
Program Services	322983	ProgramServices
Management And General	349898	ManagementAndGeneral

Other Employee Benefits OtherEmployeeBenefits

Field	Value	IRS element (for citing)
Total	1733477	Total
Program Services	832069	ProgramServices
Management And General	901408	ManagementAndGeneral

Payroll Taxes PayrollTaxes

Field	Value	IRS element (for citing)
Total	1515576	Total
Program Services	727476	ProgramServices
Management And General	788100	ManagementAndGeneral

Fees For Services Management FeesForServicesManagement

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Legal FeesForServicesLegal

Field	Value	IRS element (for citing)
Total	587042	Total
Program Services	0	ProgramServices
Management And General	587042	ManagementAndGeneral

Fees For Services Accounting FeesForServicesAccounting

Field	Value	IRS element (for citing)
Total	132090	Total
Program Services	0	ProgramServices
Management And General	132090	ManagementAndGeneral

Fees For Services Lobbying FeesForServicesLobbying

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Other FeesForServicesOther

Field	Value	IRS element (for citing)
Total	6807854	Total
Program Services	5437827	ProgramServices
Management And General	1370027	ManagementAndGeneral

Advertising Advertising

Field	Value	IRS element (for citing)
Total	33450	Total
Program Services	0	ProgramServices
Management And General	33450	ManagementAndGeneral

Office Expenses OfficeExpenses

Field	Value	IRS element (for citing)
Total	8639072	Total
Program Services	6479304	ProgramServices
Management And General	2159768	ManagementAndGeneral

Information Technology InformationTechnology

Field	Value	IRS element (for citing)
Total	1315054	Total
Program Services	657527	ProgramServices
Management And General	657527	ManagementAndGeneral

Royalties Royalties

Field	Value	IRS element (for citing)
Total	0	Total

Occupancy Occupancy

Field	Value	IRS element (for citing)
Total	6307888	Total
Program Services	4730916	ProgramServices
Management And General	1576972	ManagementAndGeneral

Travel Travel

Field	Value	IRS element (for citing)
Total	636140	Total
Program Services	254456	ProgramServices
Management And General	381684	ManagementAndGeneral

Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials

Field	Value	IRS element (for citing)
Total	0	Total

Conferences Meetings ConferencesMeetings

Field	Value	IRS element (for citing)
Total	331727	Total
Program Services	132691	ProgramServices
Management And General	199036	ManagementAndGeneral

Interest Interest

Field	Value	IRS element (for citing)
Total	305378	Total
Management And General	305378	ManagementAndGeneral

Payments To Affiliates PaymentsToAffiliates

Field	Value	IRS element (for citing)
Total	0	Total

Depreciation Depletion DepreciationDepletion

Field	Value	IRS element (for citing)
Total	5191851	Total
Program Services	3893888	ProgramServices
Management And General	1297963	ManagementAndGeneral

Insurance Insurance

Field	Value	IRS element (for citing)
Total	375001	Total
Program Services	37500	ProgramServices
Management And General	337501	ManagementAndGeneral

Other Expenses OtherExpenses (4 entries)

DescriptionDescription	TotalTotal	Program ServicesProgramServices	Management And GeneralManagementAndGeneral
SEMINARS AND EDUCATION	109437	43775	65662
DUES AND SUBSCRIPTIONS	43873	17549	26324
RECRUITMENT	29785	11914	17871
ALL OTHER EXPENSES	190943	76377	114566

Total Functional Expenses TotalFunctionalExpenses

Field	Value	IRS element (for citing)
Total	57632572	Total
Program Services	34539797	ProgramServices
Management And General	23092775	ManagementAndGeneral
Fundraising	0	Fundraising

Cash Non Interest Bearing CashNonInterestBearing

Field	Value	IRS element (for citing)
BOY	4799497	BOY
EOY	6074770	EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

Field	Value	IRS element (for citing)
BOY	12073161	BOY
EOY	8952588	EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

Field	Value	IRS element (for citing)
BOY	16842034	BOY
EOY	13761344	EOY

Accounts Receivable AccountsReceivable

Field	Value	IRS element (for citing)
BOY	1952991	BOY
EOY	153542	EOY

Receivables From Officers Etc ReceivablesFromOfficersEtc

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Receivables From Disqual Persons ReceivablesFromDisqualPersons

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Notes Loans Receivable Net OtherNotesLoansReceivableNet

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Inventories For Sale Or Use InventoriesForSaleOrUse

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

Field	Value	IRS element (for citing)
BOY	992446	BOY
EOY	850957	EOY

Field	Value	IRS element (for citing)
Land Buildings Equipment Basis	40540987	LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec	29507170	LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

Field	Value	IRS element (for citing)
BOY	13329023	BOY
EOY	11033817	EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Investments Other Securities InvestmentsOtherSecurities

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Investments Program Related InvestmentsProgramRelated

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Intangible Assets IntangibleAssets

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Assets Total OtherAssetsTotal

Field	Value	IRS element (for citing)
BOY	614069	BOY
EOY	1687696	EOY

Total Assets TotalAssets

Field	Value	IRS element (for citing)
BOY	50603221	BOY
EOY	42514714	EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

Field	Value	IRS element (for citing)
BOY	5121425	BOY
EOY	1733339	EOY

Grants Payable GrantsPayable

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Deferred Revenue DeferredRevenue

Field	Value	IRS element (for citing)
BOY	4348674	BOY
EOY	9913150	EOY

Tax Exempt Bond Liabilities TaxExemptBondLiabilities

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Escrow Account Liability EscrowAccountLiability

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Loans From Officers Directors LoansFromOfficersDirectors

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Mort Notes Pybl Secured Invest Prop MortNotesPyblSecuredInvestProp

Field	Value	IRS element (for citing)
BOY	7871489	BOY
EOY	5930394	EOY

Unsecured Notes Loans Payable UnsecuredNotesLoansPayable

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
BOY	463515	BOY
EOY	621301	EOY

Total Liabilities TotalLiabilities

Field	Value	IRS element (for citing)
BOY	17805103	BOY
EOY	18198184	EOY

Field	Value	IRS element (for citing)
Follow SFAS117	X	FollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	13945385	BOY
EOY	13838624	EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	18852733	BOY
EOY	10477906	EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	32798118	BOY
EOY	24316530	EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	50603221	BOY
EOY	42514714	EOY

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	X	InfoInScheduleOPartXI
Reconcilation Revenue Expenses	-9140521	ReconcilationRevenueExpenses
Reconcilation Other Changes	658933	ReconcilationOtherChanges
Method Of Accounting Accrual	X	MethodOfAccountingAccrual
Accountant Compile Or Review	false	AccountantCompileOrReview
FS Audited	true	FSAudited
Audit Committee	true	AuditCommittee
Financial Statement Consolidated	X	FinancialStatementConsolidated
Federal Grant Audit Required	true	FederalGrantAuditRequired
Federal Grant Audit Performed	true	FederalGrantAuditPerformed

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Publicly Supported Org170b1 Avi	X	PubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	48715607	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	40267050	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	50530395	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	55961459	CurrentTaxYearMinus1Year
Current Tax Year	27781232	CurrentTaxYear
Total	223255743	Total

Total170 Total170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	48715607	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	40267050	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	50530395	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	55961459	CurrentTaxYearMinus1Year
Current Tax Year	27781232	CurrentTaxYear
Total	223255743	Total

Field	Value	IRS element (for citing)
Amounts Subst Contributors Total	12469915	AmountsSubstContributorsTotal
Public Support Total170	210785828	PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	230227	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	492533	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	56756	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	329668	CurrentTaxYearMinus1Year
Current Tax Year	20014	CurrentTaxYear
Total	1129198	Total

Net UBI NetUBI

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	65317	CurrentTaxYearMinus4Years
Total	65317	Total

Other Income170 OtherIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	204892	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	271807	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	-8054	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	209147	CurrentTaxYearMinus1Year
Current Tax Year	850591	CurrentTaxYear
Total	1528383	Total

Field	Value	IRS element (for citing)
Total Support	225978641	TotalSupport
Gross Receipts From Admissions Etc	108384671	GrossReceiptsFromAdmissionsEtc
Public Support Pertcentage170	0.93277	PublicSupportPertcentage170
Public Support Pertcent Prior Year	0.89315	PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170	X	ThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

Field	Value	IRS element (for citing)
Contributor Number	RESTRICTED	ContributorNumber

Contributor Name Business ContributorNameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor Address US ContributorAddressUS

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Aggregate Contributions	RESTRICTED	AggregateContributions

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Art Public Exhibition Amts		ArtPublicExhibitionAmts
Held Works Of Art Amts		HeldWorksOfArtAmts

Current Year CurrentYear

Field	Value	IRS element (for citing)
Beginning Of Year Balance	6331923	BeginningOfYearBalance
Investment Earnings Or Losses	643547	InvestmentEarningsOrLosses
Other Expenditures	421940	OtherExpenditures
End Of Year Balance	6553530	EndOfYearBalance

Current Year Minus1 Year CurrentYearMinus1Year

Field	Value	IRS element (for citing)
Beginning Of Year Balance	6676003	BeginningOfYearBalance
Investment Earnings Or Losses	550880	InvestmentEarningsOrLosses
Other Expenditures	894960	OtherExpenditures
End Of Year Balance	6331923	EndOfYearBalance

Current Year Minus2 Years CurrentYearMinus2Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	6373964	BeginningOfYearBalance
Investment Earnings Or Losses	786808	InvestmentEarningsOrLosses
Other Expenditures	484769	OtherExpenditures
End Of Year Balance	6676003	EndOfYearBalance

Current Year Minus3 Years CurrentYearMinus3Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	6309126	BeginningOfYearBalance
Contributions	10000	Contributions
Investment Earnings Or Losses	422245	InvestmentEarningsOrLosses
Other Expenditures	367407	OtherExpenditures
End Of Year Balance	6373964	EndOfYearBalance

Field	Value	IRS element (for citing)
Term Endowment EOY Balance	1.00000	TermEndowmentEOYBalance
Endowments Held By Unrelated Orgs	false	EndowmentsHeldByUnrelatedOrgs
Endowments Held By Related Orgs	true	EndowmentsHeldByRelatedOrgs
Are Related Orgs Listed Schedule R	true	AreRelatedOrgsListedScheduleR
Land		Land
Buildings		Buildings

Leasehold Improvements LeaseholdImprovements

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	5137147	OtherCostOrOtherBasis
Depreciation	1961176	Depreciation
Book Value	3175971	BookValue

Equipment Equipment

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	30455525	OtherCostOrOtherBasis
Depreciation	23273818	Depreciation
Book Value	7181707	BookValue

Other Land Buildings OtherLandBuildings

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	4948315	OtherCostOrOtherBasis
Depreciation	4272176	Depreciation
Book Value	676139	BookValue

Field	Value	IRS element (for citing)
Total Of Book Value Land Buildings	11033817	TotalOfBookValueLandBuildings
Federal Income Tax Liability	0	FederalIncomeTaxLiability

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
Description	DUE TO EMPLOYEE 457(B) PLAN	Description
Amount	$621,301	Amount

Field	Value	IRS element (for citing)
Total Of Amounts	621301	TotalOfAmounts

Form990 Schedule D Part XIV Form990ScheduleDPartXIV (2 entries)

IdentifierIdentifier

ExplanationExplanation

SCHEDULE D, PART V - ENDOWMENTS

TGEN'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A SPECIFIC NUMBER OF SUMMER INTERNS EACH YEAR FOR THE NEXT 25 YEARS. THE INSTITUTE CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT.

SCHEDULE D, PART X - FIN 48 (ASC 740) FOOTNOTE

MANAGEMENT IS OF THE OPINION THAT SUBSTANTIALLY ALL OF TGEN'S AND THE FOUNDATION'S ACTIVITIES ARE RELATED TO THEIR EXEMPT PURPOSES, AND NO MATERIAL UNCERTAIN TAX POSITIONS HAVE BEEN IDENTIFIED OR RECORDED IN THE ACCOMPANYING CONSOLIDATED FINANCIAL STATEMENTS AT DECEMBER 31, 2012. TGEN AND THE FOUNDATION FILE FORMS 990 IN THE U.S. FEDERAL JURISDICTION AND COMPARABLE FORMS IN THE STATE OF ARIZONA. TAX FILINGS FOR 2008 THROUGH 2011 ARE SUBJECT TO EXAMINATION; HOWEVER, THE INSTITUTE HAS NOT BEEN NOTIFIED OF ANY SUCH EXAMINATIONS.

Schedule F IRS990ScheduleF

Accts Actvs Out US Table AcctsActvsOutUSTable

Field	Value	IRS element (for citing)
Region	Europe (Including Iceland and Greenland)	Region
Number Of Offices	0	NumberOfOffices
Number Of Employees	0	NumberOfEmployees
Type Of Activities Conducted	Program Services	TypeOfActivitiesConducted
Specific Services Provided	SOFTWARE DEVELOPMENT	SpecificServicesProvided
Total Expenditures	370000	TotalExpenditures

Field	Value	IRS element (for citing)
Subtotal Number Of Offices	0	SubtotalNumberOfOffices
Subtotal Number Of Employees	0	SubtotalNumberOfEmployees
Total Number Of Offices	0	TotalNumberOfOffices
Total Number Of Employees	0	TotalNumberOfEmployees
Subtotal Amount Spent	370000	SubtotalAmountSpent
Total Amount Spent	370000	TotalAmountSpent
Transfer To Foreign Corp	false	TransferToForeignCorp
Interest In Foreign Trust	false	InterestInForeignTrust
Own Foreign Corp	false	OwnForeignCorp
Passive Foreign Invest Co	false	PassiveForeignInvestCo
Foreign Partnership	false	ForeignPartnership
Boycott Countries	false	BoycottCountries

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
First Class Or Charter Travel	X	FirstClassOrCharterTravel
Club Dues Or Fees	X	ClubDuesOrFees
Written Policy Re T And E Expenses	true	WrittenPolicyReTAndEExpenses
Substantiation Required	true	SubstantiationRequired
Compensation Committee	X	CompensationCommittee
Independent Consultant	X	IndependentConsultant
Compensation Survey	X	CompensationSurvey
Board Or Committee Approval	X	BoardOrCommitteeApproval
Severance Payment	true	SeverancePayment
Supplemental Nonqual Retire Plan	false	SupplementalNonqualRetirePlan
Equity Based Comp Arrangement	false	EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org	false	CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs	false	CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org	false	CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs	false	CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments	true	AnyNonFixedPayments
Initial Contract Exception	false	InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (16 entries)

Base Compensation Filing OrgBaseCompensationFilingOrg	Comp Based On Related OrgsCompBasedOnRelatedOrgs	Bonus Filing OrgBonusFilingOrg	Bonus Related OrgsBonusRelatedOrgs	Other Compensation Filing OrgOtherCompensationFilingOrg	Other Compensation Related OrgsOtherCompensationRelatedOrgs	Deferred Comp Filing OrgDeferredCompFilingOrg	Deferred Comp Related OrgsDeferredCompRelatedOrgs	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg	Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs	Total Compensation Filing OrgTotalCompensationFilingOrg	Total Compensation Related OrgsTotalCompensationRelatedOrgs	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrg	Comp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs
TERESA BURLESON
381110	0	57830	0	1782	0	9744	0	6315	0	456781	0	0	0
DANIEL VON HOFF
614683	0	64946	0	4764	0	9800	0	5917	0	700110	0	0	0
SPYRO MOUSSES
250718	0	53083	0	1558	0	9750	0	8705	0	323814	0	0	0
JOHN CARPTEN
217849	0	22666	0	1622	0	51837	0	8625	0	302599	0	0	0
MICHAEL BERENS
238626	0	41695	0	36422	0	9750	0	6880	0	333373	0	0	0
DAVID DUGGAN
204013	0	53553	0	1278	0	9770	0	10718	0	279332	0	0	0
STEPHANIE MCRAE
223926	0	41321	0	18399	0	9760	0	682	0	294088	0	0	0
JAMES HARRIS
170773	0	20050	0	19161	0	12140	0	9517	0	231641	0	0	0
JEFFREY NIEVES
179646	0	74332	0	43788	0	9760	0	3403	0	310929	0	0	0
ELIZABETH MONTEMAYOR
219291	0	22820	0	2101	0	9756	0	10594	0	264562	0	0	0
EDWARD SUH
219253	0	25371	0	30626	0	9760	0	8358	0	293368	0	0	0
STEPHEN GATELY
212981	0	32596	0	1442	0	0	0	5667	0	252686	0	0	0
JOHANNA DISTEFANO
201951	0	20512	0	1730	0	9012	0	2855	0	236060	0	0	0
JEFFREY TRENT
	990045		0		95347	211539	242500		1440	211539	1329332	0	0
GALEN PERRY
180153		18731		1796		8278		8593		217551		0
DAVID CRAIG
155121		1500		1191		48774		5385		211971		0

Form990 Schedule J Part III Form990ScheduleJPartIII (3 entries)

IdentifierIdentifier	ExplanationExplanation
SCHEDULE J, PART I, LINE 1A	FIRST CLASS TRAVEL IS PERMITTED BY EXECUTIVE STAFF ONLY AND MUST, BY TGEN POLICY, BE PRE-APPROVED BY THE CHIEF OPERATING OFFICER. TGEN DOES PROVIDE MEMBERSHIP TO DR. TRENT AT THE PARADISE VALLEY COUNTRY CLUB. THIS EXPENSE WAS PRE-APPROVED BY THE CHIEF OPERATING OFFICER. THESE EXPENSES WERE NOT CONSIDERED AS TAXABLE COMPENSATION TO THE RECIPIENT. THE COUNTRY CLUB MEMBERSHIP REIMBURSEMENT IS FOR BUSINESS PURPOSES ONLY. SCHEDULE J, PART I, LINE 4A JEFFREY NIEVES RECEIVED SEVERANCE PAYMENTS IN THE AMOUNT OF $28,953 WHICH HAVE BEEN INCLUDED IN PART II, COL B(III).
SCHEDULE J, PART I, LINE 7	SOME OF THE PERSONS LISTED IN FORM 990, PART VII WERE PAID BONUSES WHICH WERE BASED ON ACCOMPLISHMENTS OF SPECIFIC MILESTONES AND/OR PERFORMANCE BASES.
SCHEDULE J, PART II	DEFERRED COMPENSATION INCLUDES RETENTION AGREEMENTS FOR THE PRESIDENT AND CHIEF SCIENTIFIC OFFICER OF THE INSTITUTE (DR. JEFFREY TRENT) AND TWO DEPUTY DIRECTORS (JOHN CARPTEN AND DAVID CRAIG). DR. TRENT IS ELIGIBLE TO RECEIVE $500,000 ON 3/12/2017 AND THE DEPUTY DIRECTORS ARE ELIGIBLE TO RECEIVE $192,000 EACH ON 11/30/2015 PAYABLE BY TGEN. AMOUNTS ACCRUED BY TGEN DURING CALENDAR YEAR 2011 UNDER THESE AGREEMENTS HAVE BEEN REPORTED IN PART II, COL C AS DEFERRED COMPENSATION AS FOLLOWS: TRENT $211,539 CARPTEN $ 42,308 CRAIG $ 42,308 DR. TRENT IS PAID BY VARI, A RELATED TAX-EXEMPT ORGANIZATION. A PORTION OF HIS SALARY IS THEN REIMBURSED BY TGEN FOR SERVICES RENDERED TO TGEN. HIS DEFERRED COMPENSATION INCLUDES $242,500 ACCRUED BY VARI DURING THE YEAR.

Schedule L IRS990ScheduleL

Form990 Schedule L Part IV Form990ScheduleLPartIV (5 entries)

RelationshipRelationship	Amount Of TransactionAmountOfTransaction	Description Of TransactionDescriptionOfTransaction	Sharing Of RevenuesSharingOfRevenues
PINNACLE WEST CAPITAL
WILLIAM POST/CEO	154832	INVESTMENT SERVICES	false
5AM SOLUTIONS
DANIEL VAN HOFF/DIRECTOR	222159	TECHNICAL CONSULTING	false
ABRAXIS BIOSCIENCE
DANIEL VAN HOFF/DIRECTOR	126369	SCIENTIFIC ADVISORY BOARD	false
ESPERANCE
DANIEL VAN HOFF/DIRECTOR	65560	SCIENTIFIC ADVISORY BOARD	false
TECH66 WILLIAM BURLESON
SPOUSE OF OFFICER	129246	CONSULTANT ON SOFTWARE PROJECT	false

Schedule M IRS990ScheduleM

Field	Value	IRS element (for citing)
Works Of Art		WorksOfArt
Art Historical Treasures		ArtHistoricalTreasures
Art Fractional Interest		ArtFractionalInterest
Books And Publications		BooksAndPublications
Clothing And Household Goods		ClothingAndHouseholdGoods
Cars And Other Vehicles		CarsAndOtherVehicles
Boats And Planes		BoatsAndPlanes
Intellectual Property		IntellectualProperty
Securities Publicly Traded		SecuritiesPubliclyTraded
Securities Closely Held Stock		SecuritiesCloselyHeldStock
Securities Prtnrshp Trust Intrsts		SecuritiesPrtnrshpTrustIntrsts
Securities Miscellaneous		SecuritiesMiscellaneous
Qualified Contrib Hist Struct		QualifiedContribHistStruct
Qualified Contrib Other		QualifiedContribOther
Real Estate Residential		RealEstateResidential
Real Estate Commercial		RealEstateCommercial
Real Estate Other		RealEstateOther
Collectibles		Collectibles
Food Inventory		FoodInventory
Drugs And Medical Supplies		DrugsAndMedicalSupplies
Taxidermy		Taxidermy
Historical Artifacts		HistoricalArtifacts
Scientific Specimens		ScientificSpecimens
Archaeological Artifacts		ArchaeologicalArtifacts

Other Non Cash Contributions Table OtherNonCashContributionsTable

Field	Value	IRS element (for citing)
Non Cash Checkbox	X	NonCashCheckbox
Description	OTHER (ATCH 1)	Description
Number Of Contributions	5	NumberOfContributions
Noncash Contribs Rptd F990	998003	NoncashContribsRptdF990
Method Of Determining Revenues	COST OR SALES PRICE	MethodOfDeterminingRevenues

Field	Value	IRS element (for citing)
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeld
Review Process Unusual NC Gifts	false	ReviewProcessUnusualNCGifts
Third Parties Used	false	ThirdPartiesUsed

Form990 Schedule M Part II Form990ScheduleMPartII

Field	Value	IRS element (for citing)
Identifier	SCHEDULE M, PART I	Identifier
Return Reference	OTHER NONCASH CONTRIBUTIONS	ReturnReference
Explanation	SEQUENCING EQUIPMENT, 3 ITEMS, REVENUES REPORTED $248,773; COMPUTER EQUIPMENT, 1 ITEM, REVENUES REPORTED $704,922; DISCOUNT ON LOAN, 1 ITEM, REVENUES REPORTED $44,308; TOTAL $998,003	Explanation

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (15 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
ORGANIZATION'S MISSION STATEMENT	FORM 990, PART I, LINE 1, AND PART III, LINE 1	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON DEVELOPING EARLIER DIAGNOSTICS AND SMARTER TREATMENTS BY EMPLOYING INNOVATIVE ADVANCES ARISING FROM THE HUMAN GENOME PROJECT AND APPLYING THEM TO THE DEVELOPMENT OF DIAGNOSTICS, PROGNOSTICS AND THERAPIES FOR CANCER, NEUROLOGICAL DISORDERS, DIABETES AND OTHER COMPLEX DISEASES. DESCRIPTION OF PROGRAM SERVICE ACCOMPLISHMENTS FORM 990, PART III, LINES 4A - 4C LINE 4A - PROGRAM SERVICE ACTIVITY #1 TGEN CLINICAL RESEARCH SERVICES CLINICIANS FOCUS ON CLINICAL TRIALS WITH TARGETED AGENTS AND GENOMICS-BASED INDIVIDUALIZED THERAPY. THE TCRS, WITH AN INITIAL FOCUS ON CANCER, ALLOWS THE UNIQUE OPPORTUNITY FOR TGEN TO TRANSITION ITS LABORATORY-BASED RESEARCH TO PATIENT CARE CENTERED ON INDIVIDUALIZED THERAPY. LINE 4B - PROGRAM SERVICE ACTIVITY #2 TGEN'S CANCER AND CELL BIOLOGY DIVISION IS WORKING TO DISCOVER VALID MARKERS AND THERAPEUTIC TARGETS FOR TREATING HUMAN DISEASE. THE DIVISION SUPPORTS LAB PROGRAMS IN BREAST CANCER, MELANOMA, LUNG CANCER, HEAD AND NECK TUMORS AS WELL AS BOTH PRIMARY AND METASTATIC BRAIN TUMORS. LINE 4C - PROGRAM SERVICE ACTIVITY #3 TGEN'S GENOTYPING TECHNOLOGY CENTER ANALYZES BITS OF DNA CALLED SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) WHICH GIVE RESEARCHERS THE POWER TO IDENTIFY DISEASE-CAUSING GENES, ASSOCIATIONS, AND DNA SIGNATURES, ALL OF WHICH HAVE PROFOUND IMPLICATIONS FOR DETECTION, PROGNOSIS AND THERAPEUTIC INTERVENTION. THE SNP GENOTYPING CENTER OFFERS INNOVATIVE SOLUTIONS THAT ADDRESS THE REQUIREMENTS FOR FLEXIBILITY, SIMPLICITY, THROUGHPUT, ECONOMY, AND ACCURACY. LINE 4D - OTHER PROGRAM SERVICES INTRODUCTION TGEN CELEBRATED ITS 10TH ANNIVERSARY IN 2012. IT WAS IN FEBRUARY 2002 THAT AN ASSEMBLY OF MORE THAN 50 ARIZONA LEADERS AND VISIONARIES IN SCIENCE, MEDICINE, GOVERNMENT AND BUSINESS GATHERED AT THE ARIZONA STATE CAPITOL TO DISCUSS THE POSSIBILITY OF ESTABLISHING ARIZONA AS A SIGNIFICANT PLAYER IN THE NEW KNOWLEDGE-BASED ECONOMY OF THE BIOMEDICAL-BIOTECHNOLOGY INDUSTRY. AS TGEN ENTERS ITS SECOND DECADE, THE INSTITUTE CONTINUES TO DEFINE ITSELF BY EMPHASIZING WHAT WE CAN DO FOR PATIENTS TODAY. THE PROSPECTS FOR INCREASINGLY SIGNIFICANT LABORATORY DISCOVERIES AND OUR TRANSLATION OF THAT NEW SCIENCE INTO CLINICAL BENEFITS FOR PATIENTS WHO HAVE NO TIME TO WAIT HEIGHTEN OUR SENSE OF URGENCY.
A NUMBER OF OUR MOST RECENT COLLABORATIONS POINT TO THIS EXCITING NEW ERA	OF GENOMIC MEDICINE. THESE INCLUDE:	- A MULTI-YEAR, MULTI-MILLION-DOLLAR CONTRACT WITH THE MULTIPLE MYELOMA RESEARCH FOUNDATION TO TRACK CHANGES IN THE GENOMES (DNA) OF AN UNPRECEDENTED 1,000-PATIENT NATIONAL STUDY OF THIS BONE MARROW CANCER. - OUR CLINICAL TRIALS PROGRAM, IN PARTNERSHIP WITH SCOTTSDALE HEALTHCARE AND BIND BIOSCIENCES, SHOWED THE SUCCESSFUL FIRST USE OF NANOPARTICLES, MICROSCOPIC DRONES, TO DELIVER TARGETED MEDICINES, SHRINKING AND EVEN ELIMINATING PATIENTS' TUMORS, ACCORDING TO A STUDY REPORTED IN THE JOURNAL SCIENCE TRANSLATIONAL MEDICINE AND PRESENTED AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). - AS REPORTED IN THE NEW ENGLAND JOURNAL OF MEDICINE, TGEN AND ITS COLLABORATORS IDENTIFIED THE FIRST MAJOR GENE MUTATION ASSOCIATED WITH HEREDITARY PROSTATE CANCER, FOLLOWING A 20-YEAR QUEST TO DISCOVER A GENETIC DRIVER FOR THIS DISEASE. - IN FEBRUARY, VISMODEGIB BECAME THE FIRST DRUG TESTED AT TGEN'S CLINIC TRIALS PROGRAM TO RECEIVE FDA APPROVAL. THIS ALSO WAS THE FIRST DRUG APPROVED BY THE FDA TO TREAT INOPERABLE BASAL CELL CARCINOMA, A TYPE OF SKIN CANCER PREVALENT IN ARIZONA. IN ADDITION, WE ANTICIPATE CONTINUING AND STRONGER COLLABORATIONS WITH ALL OUR MAJOR PARTNERS, SIGNIFICANT NEW OPPORTUNITIES WITH BIOTECH AND BIOPHARMA INDUSTRIES, AND AN ACCELERATION OF PROGRESS IN THE AREA OF COMMERCIALIZATION. TGEN'S NEW CLIA (CLINICAL LABORATORY IMPROVEMENT AMENDMENTS) LABORATORY -NAMED THE DORRANCE CLINICAL LABORATORY- ON THE 4TH FLOOR OF OUR HEADQUARTERS BUILDING ENHANCES MANY OF THESE INITIATIVE BY STREAMLINING OUR ABILITY TO PROVIDE ONCOLOGISTS WITH TIMELY GENOMIC ANALYSIS AND ACCELERATE PATIENT BENEFIT. THIS MEANS TGEN NO LONGER NEEDS TO VALIDATE ITS GENOMIC FINDINGS THROUGH AN OUTSIDE CLIA LAB BEFORE SHARING THE RESULTS WITH ONCOLOGISTS AND THEIR PATIENTS. CHIEF AMONG THESE IS THE ANNOUNCEMENT IN JULY OF $10 MILLION IN GRANTS FROM THE BEN & CATHERINE IVY FOUNDATION TO FUND TWO MULTI-YEAR PROJECTS THAT AIM TO DISCOVER THE GENOMIC ORIGINS OF GLIOBLASTOMA, A BRAIN CANCER WITH FEW TREATMENT OPTIONS FOR PATIENTS. AS PART OF THESE PROJECTS, CLINICAL TRIALS WILL TEAM US WITH SOME OF THE NATION'S MORE ESTABLISHED RESEARCH CENTERS, INCLUDING MEMORIAL SLOAN KETTERING CANCER CENTER, AND THE DANA-FARBER/HARVARD CANCER CENTER. IN EARLY OCTOBER, TGEN ANNOUNCED THE FORMATION OF THE TGEN CENTER FOR RARE CHILDHOOD DISORDERS -DUBBED C4RCD. THIS NEW CENTER CREATES A FOCAL POINT - FOR THE PUBLIC, OUR PARTNERS, AND MOST IMPORTANTLY OUR PATIENTS AND THEIR FAMILIES - WHERE WE CAN BEGIN TO UNLOCK THE MYSTERIES BEHIND THE DISEASES AND CONDITIONS, MANY OF THEM UNNAMED, WHICH FOR TOO LONG HAVE BEEN INSUFFICIENTLY ADDRESSED. WHILE MANY OF THESE CONDITIONS AFFECT ONLY A FEW CHILDREN, COLLECTIVELY THEY ACCOUNT FOR THOUSANDS OF CHILDREN IN ARIZONA AND ACROSS THE NATION. IN NOVEMBER, TGEN LAUNCHED THE KIRSTEN'S LEGACY WEBSITE, IN MEMORY OF PATIENT AND TGEN ADVOCATE KIRSTEN SANDSTROM. THE WEBSITE PROVIDES PATIENTS AND THEIR FAMILIES WITH 24-7 ACCESS TO ESSENTIAL AND COMPREHENSIVE INFORMATION ON ADRENOCORTICAL CARCINOMA (ACC), A RARE AND DEADLY FORM OF CANCER. KIRSTEN'S LEGACY IS TGEN'S RESEARCH AND CLINICAL PROGRAM FOR DEFEATING ACC, PROVIDING VALUABLE PATIENT RESOURCES AND THE LATEST UPDATES ON PROGRESS MADE BY TGEN RESEARCHERS AND CLINICIANS. THE WEBSITE AND ACTIVITIES SURROUNDING IT BUILD ON THE FOUNDING ACC EFFORTS OF TROY RICHARDS, WHOSE EFFORTS ENABLED TGEN TO ESTABLISH A NATIONAL RESEARCH-FUND INITIATIVE FOR THIS RARE BUT DEADLY DISEASE. THESE AND OTHER PROJECTS WILL TAKE FULL ADVANTAGE OF TGEN'S RECOGNIZED EXPERTISE IN GENOMIC RESEARCH, AND WILL ONLY STRENGTHEN TIES WITH OUR MANY COLLABORATORS IN ARIZONA, ACROSS THE NATION, AND AROUND THE WORLD, HELPING ENABLE ARIZONA'S BIOMEDICAL INDUSTRY TO CONTINUE ITS POSITIVE GROWTH. IN ADDITION, THE FOLLOWING OVERVIEW PROVIDES A SNAPSHOT OF RECENT PROGRESS IN SCIENTIFIC PUBLICATIONS, GRANTS, CONTRACTS, PHILANTHROPY, EDUCATION AND OUTREACH, MEDIA AND COMMUNITY RECOGNITION. PEER-REVIEWED LABORATORY RESEARCH PUBLICATIONS AND PRESENTATIONS SINCE ITS INCEPTION, TGEN'S BIOMEDICAL RESEARCH HAS FOCUSED ON THE PATIENT AS AN END POINT. TGEN FACULTY WORK TO DISCOVER THE UNDERLYING CAUSE OF DISEASE PROGRESSION AND RESISTANCE TO THERAPY AND WHY SOME INDIVIDUALS ENCOUNTER DEBILITATING DISEASES AND OTHERS LIVE HEALTHY LIVES. DRIVEN BY THE LATEST TECHNOLOGY, TGEN EFFORTS REMAIN EQUAL TO THE STRENGTHS AND CAPABILITIES OF ANY OF TODAY'S LEADING RESEARCH AND CLINICAL INSTITUTES. NOWHERE IS THIS MORE EVIDENT THAN WITH TGEN'S WHOLE GENOME SEQUENCING CAPABILITIES. WHOLE GENOME SEQUENCING ALLOWS US TO DIG DEEPER INTO THE GENOME THAN EVER BEFORE BY PROVIDING MORE INFORMATION AND INCREASING OUR PROBABILITY OF IDENTIFYING SOMETHING SIGNIFICANT. THE LONG-TERM HOPE IS THAT DOCTORS WILL LEVERAGE THIS INFORMATION TO INFORM DECISIONS ABOUT PATIENT CARE. THE RESULTS FROM THESE RESEARCH STUDIES APPEAR IN A NUMBER OF LEADING SCIENTIFIC AND MEDICAL JOURNALS, AND ADD TO THE GROWING KNOWLEDGE BASE OF MOLECULAR RESEARCH AND MEDICINE. IN 2012, TGEN RESEARCHERS PUBLISHED THEIR RESEARCH RESULTS IN NUMEROUS SCHOLARLY PEER-REVIEWED ACADEMIC JOURNALS AND THROUGH PRESENTATIONS AT LEADING NATIONAL AND INTERNATIONAL CONFERENCES. THESE INCLUDE PUBLICATION IN LEADING SCIENTIFIC JOURNALS SUCH AS NEW ENGLAND JOURNAL OF MEDICINE, PROSTATE, PLOS, BLOOD, JOURNAL OF CANCER, JOURNAL OF CLINICAL ONCOLOGY, AND A HOST OF OTHER DISEASE-ASSOCIATED PUBLICATIONS.
SELECT HIGHLIGHTS FOR 2012		1. IN A STUDY OF 144 PATIENTS WITH ADVANCED CANCER, INCLUDING COLORECTAL, OTHER GASTROINTESTINAL AND PROSTATE CANCERS, RESEARCHERS AT TGEN AND SCOTTSDALE HEALTHCARE DOCUMENTED A STATISTICALLY SIGNIFICANT DECREASE IN PROGRESSION-FREE SURVIVAL WITH EACH SUCCESSIVE STANDARD THERAPY. THE STUDY PUBLISHED NOV. 28 IN THE JOURNAL OF CANCER CONCLUDED THAT NEW THERAPIES THAT REVERSE THIS TREND MIGHT LEAD TO IMPROVED CLINICAL OUTCOMES. CITATION: "PROGRESSION-FREE SURVIVAL DECREASES WITH EACH SUBSEQUENT THERAPY IN PATIENTS PRESENTING FOR PHASE I CLINICAL TRIALS." CHRISTOPHER H. BAILEY, GAYLE JAMESON, CHAO SIMA, SHARON FLECK, ERICA WHITE, DANIEL D. VON HOFF, GLEN J. WEISS. J CANCER 2012; 3:7-13. 2. A TGEN STUDY PUBLISHED NOV. 22 IN THE JOURNAL LUNG CANCER SHOWED THAT KEY DOWNSTREAM COMPONENTS OF THE HEDGEHOG SIGNALING PATHWAY (HHSP), WHICH HAS BEEN IMPLICATED IN THE DEVELOPMENT OF MULTIPLE CANCERS, SHOW CORRELATION WITH SONIC HEDGEHOG LIGAND (SHH) EXPRESSION, SUGGESTING THAT LIGAND-DEPENDENT SIGNALING IS MORE PREVALENT IN PRIMARY NON-SMALL CELL LUNG CANCER TUMORS. CITATION: RAZ G, ALLEN KE, KINGSLEY C, CHERNI I, ARORA S, WATANABE A, LORENZO CD, EDWARDS V DK, SRIDHAR S, HOSTETTER G, WEISS GJ. "HEDGEHOG SIGNALING PATHWAY MOLECULES AND ALDH1A1 EXPRESSION IN EARLY-STAGE NON-SMALL CELL LUNG CANCER." DOI:10.1016/J.LUNGCAN.2011.10.015. 3. AN ABSTRACT PREPARED BY TGEN AND OTHERS AND PRESENTED IN DECEMBER AT THE 2011 CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM SHOWED THE VALUE OF WHOLE-GENOME SEQUENCING. RESEARCHERS AT TGEN COLLABORATED WITH US ONCOLOGY, LIFE TECHNOLOGIES AND BAYLOR'S CHARLES A. SAMMONS CANCER CENTER AND FOUND AN IMPRESSIVE RESPONSE TO AN INHIBITOR OF THE MEK/AKT CELLULAR PATHWAY IN TRIPLE-NEGATIVE BREAST CANCER. CITATION: JOYCE A. O'SHAUGHNESSY, DAVID W. CRAIG, JEFFREY KIEFER, SHRIPAD SINARI, TRACY M. MOSES, SHUKMEI WONG, JESSICA ALDRICH, ALEXIS CHRISTOFORIDES, JENNIFER DINH, TYLER ITZATT, JOANNE BLUM, AHMET KURDOGLU, BODOUR SALHIA, ANGELA BAKER, ASIM SIDDIQUI, LINH HOANG, PAUL BILLINGS, JEFFREY M. TRENT, SPYRO MOUSSES, DANIEL VON HOFF, JOHN D. CARPTEN. ABSTRACT TITLE: "NEXT GENERATION SEQUENCING REVEALS CO-ACTIVATING EVENTS IN THE MAPK AND PI3K/AKT PATHWAYS IN METASTATIC TRIPLE NEGATIVE BREAST CANCERS." 4. IN A STUDY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE, THE HOXB13 G84E VARIANT IS ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF HEREDITARY PROSTATE CANCER. ALTHOUGH THE VARIANT ACCOUNTS FOR A SMALL FRACTION OF ALL PROSTATE CANCERS, THIS FINDING HAS IMPLICATIONS FOR PROSTATE-CANCER RISK ASSESSMENT AND MAY PROVIDE NEW MECHANISTIC INSIGHTS INTO THIS COMMON CANCER. CITATION: "GERMLINE MUTATIONS IN HOXB13 AND PROSTATE-CANCER RISK." CHARLES M. EWING, M.S., ANNA M. RAY, M.S., ETHAN M. LANGE, PH.D., KIMBERLY A. ZUHLKE, B.A., CHRISTIANE M. ROBBINS, M.S., WAIBHAV D. TEMBE, PH.D., KATHLEEN E. WILEY, M.S., SARAH D. ISAACS, M.S., DORHYUN JOHNG, B.A., YUNFEI WANG, M.S., CHRIS BIZON, PH.D., GUIFANG YAN, B.S., MARTA GIELZAK, B.A., ALAN W. PARTIN, M.D., PH.D., VIJAYALAKSHMI SHANMUGAM, PH.D., TYLER IZATT, M.S., SHRIPAD SINARI, M.S., DAVID W. CRAIG, PH.D., S. LILLY ZHENG, M.D., PATRICK C. WALSH, M.D., JAMES E. MONTIE, M.D., JIANFENG XU, M.D., DR.P.H., JOHN D. CARPTEN, PH.D., WILLIAM B. ISAACS, PH.D., AND KATHLEEN A. COONEY, M.D. N ENGL J MED 2012; 366:141-149 JAN, 2012. 5. WHOLE GENOME SEQUENCING OF A RARE NASAL TRACT CANCER CALLED OLFACTORY NEUROBLASTOMA IDENTIFIED GENETIC MUTATIONS THAT COULD BE FUTURE TARGETS OF ADVANCED PRECISION-MEDICINE DRUG DEVELOPMENT, ACCORDING TO A STUDY PUBLISHED IN THE JOURNAL PLOS ONE. A COMPARISON OF A PATIENT'S NORMAL AND TUMOR DNA IDENTIFIED SIGNIFICANT GENE MUTATIONS, SELECTED BASED ON CLINICAL RELEVANCE OF THE TARGET GENES AND THEIR ASSOCIATION WITH THE PROGRESSION OF CANCER. CITATION: WEISS GJ, LIANG WS, IZATT T, ARORA S, CHERNI I, ET AL. (2012). "PAIRED TUMOR AND NORMAL WHOLE GENOME SEQUENCING OF METASTATIC OLFACTORY NEUROBLASTOMA." PLOS ONE 7(5): E37029. DOI:10.1371/JOURNAL.PONE.0037029. 6. IN A SCAN OF 1,233 PROSTATE CANCER FAMILIES, RESEARCHERS IDENTIFIED SUGGESTIVE EVIDENCE FOR LINKAGE IN CHROMOSOMES 4 AND 8, WITH ADDITIONAL REGIONS IMPLICATED IN SUBSETS OF FAMILIES DEFINED BY AGE AT DIAGNOSIS, DISEASE AGGRESSIVENESS, OR NUMBER OF AFFECTED MEMBERS. THESE RESULTS, PUBLISHED IN THE MARCH ISSUE OF THE JOURNAL PROSTATE, WILL BE USEFUL IN PRIORITIZING FUTURE SUSCEPTIBILITY GENE DISCOVERY EFFORTS IN THIS COMMON CANCER. CITATION: "CHROMOSOMES 4 AND 8 IMPLICATED IN A GENOME WIDE SNP LINKAGE SCAN OF 762 PROSTATE CANCER FAMILIES COLLECTED BY THE ICPCG." JOHN CARPTEN AND 37 COLLABORATORS, INCLUDING THE INTERNATIONAL CONSORTIUM FOR PROSTATE CANCER GENETICS. PROSTATE. 2012 MAR;72(4):410-26. DOI: 10.1002/PROS.21443. 7. IN A STUDY OF HOW BRAIN CANCER CELLS SPREAD, RESEARCHERS FOUND THAT THE CDC42 GENES AND THE PROTEINS ECT2 AND TRIO HAVE AN EFFECT ON HOW THE TWEAK-FN14 SIGNALING PATHWAY STIMULATES THE MIGRATION AND INVASION OF GLIOMA CELLS. THESE FINDINGS, PUBLISHED IN MAY IN THE JOURNAL MOLECULAR CANCER RESEARCH, PROVIDE A POTENTIAL INNOVATIVE DRUG TARGET FOR GLIOMA THERAPY. CITATION: "CDC42 AND THE GUANINE NUCLEOTIDE EXCHANGE FACTORS ECT2 AND TRIO MEDIATE FN14-RAC1-INDUCED MIGRATION AND INVASION OF GLIOBLASTOMA CELLS." SHANNON FORTIN, NHAN TRAN AND 8 OTHER COLLABORATORS. MOL CANCER RES. 2012 JUL;10(7):958-68. EPUB 2012 MAY 9. 8. FOLLOWING UP ON A 2009 OUTBREAK OF ANTHRAX AMONG HEROIN USERS IN SCOTLAND, THIS STUDY USED WHOLE GENOME SEQUENCING TO DISCOVER THAT A NEW OUTBREAK OF ANTHRAX IN SCOTLAND, ENGLAND AND GERMANY WAS LINKED TO TURKEY, AND NOT TO PREVIOUS ISOLATES FROM SCOTLAND OR AFGHANISTAN. CITATION: PRICE EP, SEYMOUR ML, SAROVICH DS, LATHAM J, WOLKEN SR, MASON J, ET AL. "MOLECULAR EPIDEMIOLOGIC INVESTIGATION OF AN ANTHRAX OUTBREAK AMONG HEROIN USERS, EUROPE." EMERG INFECT DIS. 2012 AUG DOI: 10.3201/EID1808.111343. 9. WHOLE GENOME SEQUENCING WAS USED FOR THE FIRST TIME TO SIMULTANEOUSLY PROFILE THREE PATIENTS WITH PANCREATIC CANCER IN THIS TGEN-LED STUDY PUBLISHED IN OCTOBER BY PLOS ONE. THE ANALYSIS, ASSISTED BY SCOTTSDALE HEALTHCARE AND MAYO CLINIC, SHOWED THAT WGS "IS AN OBVIOUS AND POWERFUL METHOD FOR ADVANCING OUR UNDERSTANDING OF PANCREATIC CANCER." IN ALL THREE CASE STUDIES, THE REPORT FOUND MULTIPLE POTENTIAL THERAPEUTIC TARGETS, HIGHLIGHTING THE NEED TO STUDY THE FULL SPECTRUM OF THE GENOME AND RE-EMPHASIZING THE NEED TO DEVELOP MULTIPLE AVENUES OF THERAPEUTICS TO MATCH THE SPECIFIC MEDICAL CHALLENGES OF EACH PATIENT. CITATION: "GENOME-WIDE CHARACTERIZATION OF PANCREATIC ADENOCARCINOMA PATIENTS USING NEXT GENERATION SEQUENCING." LIANG WS, CRAIG DW, CARPTEN J, BORAD MJ, DEMEURE MJ, ET AL. (2012) GENOME-WIDE CHARACTERIZATION OF PANCREATIC ADENOCARCINOMA PATIENTS USING NEXT GENERATION SEQUENCING. PLOS ONE 7(10): E43192. DOI:10.1371/JOURNAL.PONE.0043192 10. IN ANOTHER EFFORT TO DISCOVER BETTER THERAPIES FOR PANCREATIC CANCER, THIS STUDY PUBLISHED IN 2012 IN THE JOURNAL OF CLINICAL ONCOLOGY SCANNED THE RECORDS OF MORE THAN 1,000 PATIENTS, RESULTING IN THE IDENTIFICATION OF NUMEROUS ACTIONABLE TARGETS FOR FURTHER RESEARCH. THE STUDY REITERATED THE IMPORTANCE OF KRAS MUTATIONS, SUGGESTED TOPO2 INHIBITORS FOR EXAMINATION, AND ENCOURAGED THE POSSIBLE EXPLORATION OF OTHER CELLULAR PATHWAYS, INCLUDING DNA REPAIR AND AMINO ACID TARGETS. THIS STUDY WAS SUPPORTED IN PART BY A STAND UP TO CANCER DREAM TEAM AWARD. CITATION: "ACTIONABLE TARGETS IN PANCREATIC CANCER DETECTED BY IMMUNOHISTOCHEMISTRY (IHC), MICROARRAY (MA) FLUORESCENT IN SITU HYBRIDIZATION (FISH), AND MUTATIONAL ANALYSIS." DANIEL D. VON HOFF, RAMESH K. RAMANATHAN, DOUGLAS B. EVANS, MICHAEL J. DEMEURE, TODD MANEY, BRIAN WRIGHT, ZORAN GATALICA, MATTHEW JEROME MCGINNISS; VIRGINIA G. PIPER CANCER CENTER AT SCOTTSDALE HEALTHCARE/TGEN, SCOTTSDALE, AZ; MEDICAL COLLEGE OF WISCONSIN, MILWAUKEE, WI; TRANSLATIONAL GENOMIC RESEARCH INSTITUTE, PHOENIX, AZ; CARIS LIFE SCIENCES, PHOENIX, AZ. J CLIN ONCOL 30, 2012 (SUPPL; ABSTR 4013).
CLINICAL RESEARCH / CLINICAL TRIALS		MEDICINE IS AT A CROSSROADS. GENOMIC AND OTHER -OMIC GENERATED INFORMATION CAN GREATLY INFORM THERAPEUTIC DECISIONS BY PROVIDING A GREATER UNDERSTANDING OF THE UNDERLYING BIOLOGICAL DEFECTS ASSOCIATED WITH A PARTICULAR DISEASE OR DISORDER. SINCE DAY ONE AT TGEN, OUR GOAL HAS ALWAYS BEEN TO CHAMPION GENOMIC-BASED MEDICINE BY USING AN INDIVIDUAL'S GENETIC PROFILE TO GUIDE CLINICAL DECISIONS ABOUT PREVENTING, DIAGNOSING, AND TREATING HIS OR HER DISEASE. MATCHING THE RIGHT PATIENT WITH THE RIGHT THERAPY APPROPRIATE TO THE UNDERLYING GENETICS OF THEIR SPECIFIC DISEASE WILL MEAN THAT A HIGHER PROPORTION OF PATIENTS WILL BENEFIT. THERE WILL BE MORE DURABLE RESPONSES AND LONGER SURVIVAL TIMES. THERE WILL BE LESS UNNECESSARY TOXICITY, EXPENSE, AND TIME WASTED ON INEFFECTIVE THERAPIES. ESTABLISHED IN 2006, THE VIRGINIA G. PIPER CANCER CENTER (VGPCC) CLINICAL TRIALS PROGRAM AT SCOTTSDALE HEALTHCARE, A STRATEGIC ALLIANCE WITH SCOTTSDALE HEALTHCARE (SHC), PROVIDES A DIRECT CLINICAL RESEARCH SITE FOR TGEN. DR. DANIEL VON HOFF, TGEN'S PHYSICIAN-IN-CHIEF, SERVES AS CHIEF SCIENTIFIC OFFICER. PROGRAM CLINICIANS FOCUS ON CLINICAL TRIALS WITH TARGETED AGENTS AND GENOMICS-BASED INDIVIDUALIZED THERAPY. THE VGPCC CLINICAL TRIALS PROGRAM, WITH AN INITIAL FOCUS ON CANCER, ALLOWS THE UNIQUE OPPORTUNITY FOR TGEN TO TRANSITION ITS LABORATORY-BASED RESEARCH TO PATIENT CARE CENTERED ON INDIVIDUALIZED THERAPY. PROGRAM STAFF CURRENTLY WORKING ON THE PHASE I CLINICAL TRIALS PATIENT PARTICIPATION IN CLINICAL TRIALS INCLUDE: - OVER 300 VISITS PER MONTH - NEARLY 40 NEW PATIENTS PER MONTH - OVER 400 PATIENT SAMPLES COLLECTED PER MONTH. 2012 HIGHLIGHTS FEBRUARY 1, 2012 - A NEW SKIN CANCER DRUG TESTED FOR THE FIRST TIME IN THE WORLD FIVE YEARS EARLIER BY TGEN AND SCOTTSDALE HEALTHCARE RECEIVES EXPEDITED APPROVAL BY THE U.S. FOOD AND DRUG ADMINISTRATION, A REMARKABLE ACCOMPLISHMENT IN NEW DRUG DEVELOPMENT. APRIL 3, 2012 - RESULTS OF THE FEASIBILITY OF SELECTING TREATMENT BASED ON INDIVIDUAL MOLECULAR CHARACTERISTICS WAS DEMONSTRATED IN A FIRST-OF-ITS KIND PANCREATIC CANCER CLINICAL TRIAL WAS REPORTED BY TGEN / SCOTTSDALE HEALTHCARE AT AACR ANNUAL MEETING. JUNE 13, 2012 - TGEN / SCOTTSDALE HEALTHCARE STUDY AN INVESTIGATIONAL DRUG THAT ACTS LIKE A TROJAN HORSE TO DELIVER CANCER KILLING AGENTS FOR PANCREATIC. THE PHASE 2 CLINICAL TRIAL TESTS THE EFFECTIVENESS AND SAFETY OF INNO-206 IN PATIENTS WITH ADVANCED PANCREATIC DUCTUAL ADENOCARCINOMAS (PDA) WHO HAVE NOT RESPONDED TO PRIOR STANDARD TREATMENT. AUGUST 29, 2012 - A PHASE I/II, MULTI-CENTER TRIAL DESIGNED TO TEST THE SAFETY AND PRELIMINARY EFFICACY OF A FIRST IN CLASS CANCER TREATMENT OPENS AT TGEN / SCOTTSDALE HEALTHCARE CLINIC. PR610 IS DESIGNED TO ACTIVATE IN TISSUES WITH LOW LEVELS OF OXYGEN, WHICH IS CHARACTERISTIC OF MANY CANCERS. GRANT SUPPORT GRANT FUNDING IS OFTEN THE LIFEBLOOD OF RESEARCH. IN 2012, TGEN INVESTIGATORS SUBMITTED 145 GRANTS TOTALING $115M. TGEN WAS AWARDED 9 GRANTS, TOTALING $1.4M, WITH AN ADDITIONAL 71 GRANTS PENDING AND IN REVIEWS TOTALING $70M. ADDITIONALLY, TGEN RECEIVED $12.8M FROM 2010 AND 2011 PENDING GRANTS, BRINGING THE AWARDED TOTAL FOR 2012 TO $14.2M. TGEN'S SUCCESS RATE CURRENTLY RESTS AT 23 PERCENT OF TOTAL GRANTS SUBMITTED, PLACING THE INSTITUTE NEARLY 3 PERCENT HIGHER THAN THE NATIONAL AVERAGE (NIH OVERALL SUCCESS RATE). 1. THREE-YEAR GRANT FROM STAND UP TO CANCER (SU2C) AND MELANOMA RESEARCH ASSOCIATION TOTALING $5,981,538 TO DR. JEFFREY TRENT FOR A PERSONALIZED MEDICINE STUDY OF PATIENTS WITH BRAF WILD-TYPE MELANOMA. 2. THREE-YEAR GRANT FROM THE MUSCULAR DYSTROPHY ASSOCIATION TOTALING $208,486 TO DR. LISA BAUMBACH-REARDON TO STUDY MUSCULAR DYSTROPHY. 3. UNDER SUBCONTRACT, A FIVE-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) TOTALING $124,992 TO DR. MATTHEW HUENTELMAN TO STUDY ALZHEIMER'S DISEASE AND SUPPORT THE ARIZONA ALZHEIMER'S DISEASE CORE CENTER (ADCC). 4. FIVE-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TOTALING $2.5 MILLION TO DR. MICHAEL BERENS TO SEARCH FOR NEW DRUG TARGETS IN GLIOBLASTOMA AND OTHER CANCERS THAT COULD BE SHARED WITH THE CANCER TARGET DISCOVERY AND DEVELOPMENT NETWORK. 5. THREE-YEAR GRANT UNDER SUBCONTRACT WITH THE UNIVERSITY OF MICHIGAN FROM SUSAN G. KOMEN FOR THE CURE TOTALING $533,180 TO DR. JEFFREY TRENT TARGETING STEM CELLS IN TRIPLE-NEGATIVE BREAST CANCER IN DIFFERENT RACIAL POPULATIONS, INCLUDING CLINICAL TRIALS. 6. TWO-YEAR GRANT FROM NATIONAL INSTITUTES OF HEALTH TOTALING $531,755 TO DR. PAUL KEIM TO STUDY CRYPTOCOCCUS GATTII BY SEQUENCING 200 GENOMES OF THIS TYPE OF FUNGUS, INCLUDING A PARTICULARLY VIRULENT AMERICAN STRAIN DESIGNATED AS VGIIC. 7. TWO-YEAR SUBCONTRACT GRANT (MAYO CLINIC IS PRIME) FROM ACCELERATE BRAIN CANCER CURE INC. TOTALING $262,480 TO DR. JOHN CARPTEN TO SHOW HOW WHOLE GENOME SEQUENCING CAN BE USED TO IDENTIFY CLINICALLY ACTIONABLE VULNERABILITIES IN GLIOBLASTOMA MULTIFORME (GBM) PATIENTS. 8. FOUR-YEAR GRANT FROM THE DEPARTMENT OF DEFENSE TOTALING $938,715 TO DR. PAUL KEIM TO CONDUCT GENOMIC PROFILES OF THE VARIOUS NEAR-NEIGHBOR FORMS OF THE PATHOGEN B. PSEUDOMALLEI, A BIOLOGICAL WARFARE AGENT. NAU IS PRIME ON THIS SUBCONTRACT. 9. UNDER SUBCONTRACT FROM THE UNIVERSITY OF GEORGIA, A FIVE-YEAR GRANT FROM THE NATIONAL CANCER INSTITUTE (NIH) TOTALING $663,574 TO DR. DANIEL VON HOFF TO IDENTIFY POTENTIAL GLYCOMARKERS FOR PANCREATIC AND BREAST CANCER IN AN EFFORT TOWARD EARLY CANCER DETECTION. 10. UNDER SUBCONTRACT FROM NAU, A FIVE-YEAR GRANT FROM THE NATIONAL SCIENCE FOUNDATION TOTALING $499,759 TO DR. LANCE PRICE TO STUDY MICROBIAL BIODIVERSITY IN RELATION TO SOIL CARBON CYCLES. ENTERPRISE EFFORTS, COLLABORATION AND JOB CREATION TGEN'S OFFICES OF BUSINESS DEVELOPMENT AND TECHNOLOGY TRANSFER WORK TO DEVELOP AN APPROPRIATE ADMINISTRATIVE STRUCTURE TO HANDLE COMMERCIALIZATION OF ITS INTELLECTUAL PROPERTY, AS WELL AS DEVELOPING EFFECTIVE WAYS TO PARTNER WITH THE COMMERCIAL SECTOR. THE TECHNOLOGY TRANSFER OFFICE (TTO) FACILITATES AND ACCELERATES THE COMMERCIALIZATION OF TGEN'S SCIENTIFIC DISCOVERIES FOR THE BENEFIT OF HUMAN HEALTH BY: A. IDENTIFYING, PATENTING AND LICENSING NEW TECHNOLOGY; B. FACILITATING ACCESS AND EXCHANGE OF RESEARCH MATERIALS, TECHNOLOGIES, AND DATA VIA MATERIAL TRANSFER AGREEMENTS (MTAS) OR CONFIDENTIAL DISCLOSURE AGREEMENTS (CDAS); C. NEGOTIATING COLLABORATIVE RESEARCH AGREEMENTS; AND D. ASSISTING IN THE FORMATION OF START-UP COMPANIES WHEN APPROPRIATE.
INVENTION DISCLOSURES		TGEN SCIENTISTS WORK WITH THE OFFICE OF TECHNOLOGY TRANSFER (OTT) TO FILE INVENTION DISCLOSURES AS THE FIRST STEP TOWARD A POSSIBLE PATENT APPLICATION OR OTHER APPROPRIATE FORM OF INTELLECTUAL PROPERTY PROTECTION. TGEN FILED 24 INVENTION DISCLOSURES IN 2012 BASED ON DISCOVERIES STEMMING FROM TGEN-LED RESEARCH, AND 16 PROVISIONAL PATENT APPLICATIONS. SPIN OFFS TGEN FORMED TWO SINGLE MEMBER LLCS (TRANSLATIONAL SYSTEMS LLC AND ASHION ANALYTICS LLC) IN 2012. CONTRACTS AND COLLABORATIONS TGEN SIGNED A TOTAL OF 434 CONTRACTS IN 2012, BROKEN DOWN AS FOLLOWS: A. 104 CONFIDENTIAL DISCLOSURE AGREEMENTS (CDA) B. 64 MATERIAL TRANSFER AGREEMENTS (MTA) C. 45 RESEARCH COLLABORATIONS (MANY WITH LOCAL AND STATE AFFILIATIONS), INCLUDING AGREEMENTS THAT FURTHER RESEARCH INTO A HOST OF DISEASES, INCLUDING BRAIN CANCER, MELANOMA, ALZHEIMER'S AND AUTISM. D. 29 CONSULTING AGREEMENTS E. 80 PROFESSIONAL SERVICES AGREEMENTS F. 4 COMMERCIALIZATION LICENSES G. 108 AGREEMENTS COVERING MISCELLANEOUS ACTIVITIES 1. MAYO CLINIC - "A PILOT STUDY EXAMINING THE UTILITY OF WHOLE GENOME TUMOR SEQUENCING (WGS) AND WHOLE GENOME EXPRESSION PROFILE TO FIND POTENTIAL TARGETS FOR THERAPY IN PATIENTS WITH ADVANCED CANCER" (DRS. CARPTEN, VON HOFF, RAMANATHAN & STEWART, BORAD, FONSECA, RAMANATHAN, VON HOFF) 2. MAYO CLINIC - CONTINUATION OF THE INTEGRATED CANCER GENOME RESEARCH FOCUSED ON NEXT-GENERATION SEQUENCING AND BIOINFORMATIC ANALYSIS. 3. CENTERS FOR DISEASE CONTROL RESEARCH (CDC) COLLABORATION AGREEMENT - PROJECTS INVOLVING ANTIBIOTIC-RESISTANT AND HEALTHCARE-ASSOCIATED BACTERIAL PATHOGENS (DRS. ENGELTHALER, LIMBAGO & MACCANNELL) 4. PHOENIX CHILDREN'S HOSPITAL RESEARCH PLAN 01 - PROFESSIONAL SERVICES PROVIDED TO TGEN BY DR. RATAN BHARDWAJ (DRS. BERENS & CRAIG) 5. SCOTTSDALE HEALTHCARE 2ND AMENDMENT TO RESEARCH PLAN 02 - EXTENDS TERM THROUGH 3/25/13 (DRS. BUSSEY & DEMEURE) 6. UNIVERSITY OF ARIZONA RESEARCH PLAN - "ASSESSING PRIMARY CILIA AND CENTROSOMES IN BASAL CELL CARCINOMA" (DRS. WEISS & MCDERMOTT) 7. MARICOPA INTEGRATED HEALTH SYSTEM (MIHS) AMENDMENT ONE TO RESEARCH COLLABORATION AGREEMENT - EXTENDS TERM THROUGH JUNE 20, 2015 8. PHOENIX CHILDREN'S HOSPITAL AMENDMENT ONE TO RESEARCH PLAN - "PROFESSIONAL SERVICES AGREEMENT FOR DR. RATAN BHARDWAJ" - REVISES PLANNING SUMMARY AND FINANCIAL PLAN (DRS. BHARDWAJ, CRAIG & BERENS) 9. VETERINARY NEUROLOGICAL CENTER RESEARCH COLLABORATION AGREEMENT & RESEARCH PLAN 01 - "CANINE BRAIN TUMOR DENDRITIC CELL VACCINE" (DRS. DECKER, CRAIG & BHARDWAJ) 10. TEXAS ENGINEERING EXPERIMENT STATION AMENDMENT THREE TO MEMORANDUM OF UNDERSTANDING (DR. DOUGHERTY) - 11. HILL'S PET NUTRITION RESEARCH - "EVALUATING THE IMPACTS OF PREBIOTICS AND PROBIOTICS ON THE FELINE GI MICROBIOME" (DR. PRICE) 12. MAYO CLINIC STATEMENT OF WORK 11 - "KNOWLEDGE MINING DATA FROM HT-RNAI SCREEN ON ANAPLASTIC THYROID CANCER CELLS" (DRS. COPLAND & KIEFER) 13. ILLUMINA AMENDMENT ONE TO STATEMENT OF WORK 3 - EXTENDS COLLABORATION PLANNING PERIOD THROUGH SEPTEMBER 17, 2012 14. SPECTRUM HEALTH HOSPITALS RESEARCH COLLABORATION AGREEMENT AND RESEARCH PLAN 01 - "UNDERSTANDING THE SHIFTS IN INTESTINAL GUT FLORA IN CHEMOTHERAPY PATIENTS AT RISK FOR INTESTINAL MUCOSITIS (DRS. PRICE & KURT) 15. MAYO CLINIC FIRST AMENDMENT TO RESEARCH PLAN (SELINSKY) - FOR PROJECT LUNG, EXTENDS TERM THROUGH DECEMBER 31, 2012 JOB CREATION SEVEN NEW FULL-TIME EQUIVALENT POSITIONS WERE CREATED IN 2012 WITH SALARIES AND BENEFITS TOTALING $557,329. SALARIES FOR TEMPORARY POSITIONS (THOSE POSITIONS CREATED FOR A FINITE PERIOD OF TIME) TOTALED $106,745 AND STUDENT SALARIES WERE JUST OVER $332,469, BRINGING THE OVERALL TOTAL TO $996,543. THIS BROUGHT THE TOTAL FOR TGEN STAFF TO 257 IN 2012, OF WHICH 78 PERCENT HOLD A COLLEGE DEGREE AND 46 PERCENT HOLD AN ADVANCED DEGREE. 2012 POSITIONS FILLED (NEW AND REPLACEMENTS) INCLUDED: ADMINISTRATIVE ASSISTANT ASSISTANT DEVELOPMENT DIRECTOR ASSOCIATE BIOINFORMATICIAN BUSINESS ANALYST ENTERPRISE APPLICATIONS DIRECTOR LAB MANAGER POST-DOC FELLOW PROJECT ACCOUNTING DIRECTOR PURCHASING AGENT QUALITY ASSURANCE SPECIALIST RESEARCH ASSOCIATE RESEARCH ASSOCIATE II RESEARCH TECHNICIAN SOFTWARE ENGINEER SR. HIGH-PERFORMANCE COMPUTING ENGINEER STAFF SCIENTIST EDUCATION AND PUBLIC OUTREACH TGEN SCIENCE EDUCATION AND COMMUNITY OUTREACH IS GEARED TOWARD THE DEVELOPMENT OF A TALENTED BIOSCIENCE WORKFORCE IN ARIZONA, AND INCREASED PUBLIC FLUENCY IN GENOMIC SCIENCE AND TRANSLATIONAL MEDICINE. 2012 HIGHLIGHTS INCLUDE: INTERNSHIPS 2012 SAW 45 ARIZONA STUDENTS PARTICIPATE IN TGEN'S FLAGSHIP, PAID SUMMER INTERNSHIP PROGRAM, HELIOS SCHOLARS AT TGEN. COHORT DEMOGRAPHICS: 82 PERCENT ATTENDED PUBLIC ACADEMIC INSTITUTIONS; 27 PERCENT SELF-IDENTIFIED AS RACES/ETHNICITIES UNDERREPRESENTED IN THE BIOSCIENCES; 51 PERCENT ARE FEMALE; 13 PERCENT WERE IN HIGH SCHOOL, 82 PERCENT IN COLLEGE AND 5 PERCENT IN GRADUATE OR MEDICAL SCHOOL. TGEN BEGAN TO RE-ENGAGE THE NEARLY 250 HELIOS SCHOLARS ALUMNI BY DEVELOPING A TRACKING DATABASE AND HOSTING THE FIRST ALUMNI NETWORKING RECEPTION. TGEN INTENDS TO MAINTAIN RELATIONSHIPS WITH ALUMNI WHO CAN MENTOR CURRENT INTERNS AND ACT AS AMBASSADORS FOR ARIZONA BIOSCIENCES IN THEIR SOCIAL AND PROFESSIONAL NETWORKS. NEW IN 2012 IS THE IVY NEUROLOGICAL SCIENCES INTERNSHIP PROGRAM, A SUMMER AND FALL PAID INTERNSHIP PROGRAM SUPPORTING THREE HIGH SCHOOL STUDENTS AND TWO UNDERGRADUATES ANNUALLY FOR NEUROLOGICAL DISEASE RESEARCH AND A CLINICAL TRAINING MODULE. TGEN PILOTED A PARTNERSHIP WITH DUKE UNIVERSITY TO BRING TWO DUKE UNDERGRADUATES INTERESTED IN BIOINFORMATICS AND GENOMICS TO STUDY AT TGEN FOR A 10-WEEK INTERNSHIP. THIS BROADENED AWARENESS OF TGEN NATIONALLY AND IT IS HOPED THAT STUDENT SHARING WILL SET THE STAGE FOR FUTURE FACULTY COLLABORATIONS. OUTSIDE OF THESE PROGRAMS, TGEN HOSTED APPROXIMATELY 15 SUMMER INTERNS, AND NEARLY 50 NON-PROGRAM ACADEMIC YEAR INTERNS THROUGHOUT ALL TGEN RESEARCH DIVISIONS INCLUDING LABORATORY AND CLINICAL RESEARCH, RESEARCH ADMINISTRATION, AND MATHEMATICS AND COMPUTATIONAL BIOLOGY RESEARCH. EDUCATIONAL TOURS TGEN HOSTED OVER 50 PUBLIC TOURS (500+ ATTENDEES) FOR STUDENTS, TEACHERS, COMMUNITY ORGANIZATIONS AND THE GENERAL PUBLIC. TGEN ALSO HOSTED AN IN-DEPTH PUBLIC TOUR, "DNA BY MOONLIGHT," WITH NEARLY 50 ATTENDEES IN SUPPORT OF THE INAUGURAL YEAR OF THE ARIZONA SCITECH FESTIVAL. IN MARCH 2012, TGEN SUPPORTED THREE LOCAL HIGH SCHOOL STUDENTS FROM THE BE A LEADER FOUNDATION FOR THE ANNUAL SHADOW A PROFESSIONAL DAY.
COMMUNITY OUTREACH		TGEN FACULTY AND STAFF PARTICIPATED IN LOCAL, REGIONAL AND STATEWIDE SCIENCE FAIRS, AND SHARED INSIGHT AND RESEARCH INFORMATION AT COMMUNITY EVENTS, CAREER DAYS, EXPOS, AND EXPERT PANELS AT MIDDLE AND HIGH SCHOOLS, COMMUNITY COLLEGES, UNIVERSITIES, ETC. TGEN IS REPRESENTED ON THE LOCAL ARRANGEMENTS COMMITTEE, AND RECRUITS JUDGES AND VOLUNTEERS, FOR THE UPCOMING THREE-YEAR PHOENIX ROTATION OF THE INTEL INTERNATIONAL SCIENCE AND ENGINEERING FAIR. TGEN STAFF SERVED ON LOCAL ADVISORY COMMITTEES AND BOARDS IN SUPPORT OF SCIENCE EDUCATION SUCH AS THE ARIZONA SCIENCE CENTER PATHWAYS PROGRAM DESIGN TEAM, THE CHANDLER-GILBERT COMMUNITY COLLEGE BIOMEDICAL RESEARCH TECHNOLOGY PROGRAM ADVISORY BOARD, THE FLINN SCHOLARS PROGRAM REVIEW TEAM, AND SEVERAL OTHERS. MEDIA/ON-LINE TGEN REMAINS ACTIVE IN PURSUING POSITIVE EARNED MEDIA EXPOSURE FOR THE INSTITUTE'S RESEARCH AND PHILANTHROPIC ACTIVITIES. MEDIA EXPOSURE RAISES AWARENESS AND BRINGS ADDED CREDIBILITY TO THE INSTITUTE AND THE STATE. IN TOTAL, TGEN RECEIVED GREATER THAN 1000 MEDIA MENTIONS IN 2012 IN VARIOUS TRADE AND PUBLIC MEDIA: LOCALLY, NATIONALLY AND INTERNATIONALLY. WHILE CITING TGEN SPECIFICALLY, THESE ARTICLES AND NEWS BRIEFS HELP BUILD A GREATER PRESENCE FOR THE CONTINUOUSLY EXPANDING BIOMEDICAL SCIENCE INITIATIVES OCCURRING IN ARIZONA. MEDIA OUTLETS INCLUDE: ABC NEWS, ARIZONA DAILY SUN, THE ARIZONA REPUBLIC, BLOOMBERG NEWS, THE BOSTON HERALD, CHICAGO TRIBUNE, CNN, DOW JONES, FLAGSTAFF TODAY, FORBES, THE INDEPENDENT (LONDON), KAET (CHANNEL 8), KNAU (FLAGSTAFF), KPNX (CHANNEL 12), THE LOS ANGELES TIMES, NEW YORK TIMES, NATIONAL PUBLIC RADIO, PHOENIX BUSINESS JOURNAL, PHOENIX MAGAZINE, USA TODAY, U.S. NEWS & WORLD REPORT, THE WASHINGTON POST, WIRED. A NEW LOGO AS TGEN ENTERS ITS SECOND DECADE, WE DO SO WITH A NEW LOGO AND WEBSITE THAT MORE SUCCINCTLY REFLECTS TGEN'S RESEARCH ENVIRONMENT AND MISSION AND THE RAPIDLY CHANGING TECHNOLOGIES THAT HAVE ACCELERATED OUR PACE OF DISCOVERY OVER THE PAST DECADE. THE NEW LOOK REFLECTS TGEN'S CONTINUED FOCUS ON THE PATIENT, PARTICULARLY IN THE AREAS OF CANCER, NEUROLOGY AND RARE CHILDHOOD DISORDERS. THESE CHANGES HAVE ALTERED THE PUBLIC VIEW OF HOW GENOMICS CAN POSITIVELY IMPACT SOCIETY IN TERMS OF MEDICAL CARE AND SO MANY ADDITIONAL FACETS OF LIFE. TGEN HAS ALWAYS BEEN FORWARD THINKING IN TERMS OF OUR RESEARCH AND ABILITY TO IMPACT PATIENT CARE, AND OUR NEW LOGO IS A FIRST STEP IN COMMUNICATING TO THE VARIOUS COMMUNITIES WITH INTEREST IN TGEN, THE VALUES THAT GUIDE OUR MISSION OF SETTING A NEW STANDARD OF CARE THROUGH THE EVOLUTION OF GENOMICS-BASED TECHNOLOGIES AND MEDICINE. THE NEW LOGO SHOWCASES THE INNOVATIVE SPIRIT OF TGEN, WHILE PAYING HOMAGE TO THE ORIGINAL LOOK BY INCORPORATING FORMS THAT COMPRISE THE ABSTRACT DEPICTION OF THE DOUBLE HELIX. THE CLEAN AND CONTEMPORARY (YET CLASSIC) DESIGN ILLUSTRATES THE ADVANCEMENT OF THE HEALTH AND SCIENCE FIELDS. THE INTERTWINING ELEMENTS EXEMPLIFY HOW HEALTH AND BIOLOGY WORK TOGETHER IN OUR MISSION TO TREAT AND CURE A VARIETY OF GENETIC DISEASES AND DISORDERS. REDEFINED ON-LINE PRESENCE WE'VE ALSO REDEFINED OUR ONLINE PRESENCE WITH A REDEVELOPED WEBSITE, THROUGH WHICH OUR VARIED STAKEHOLDERS CAN STAY UP-TO-DATE ON THE LATEST RESEARCH FINDINGS, PATIENT ADVANCES, PUBLIC EVENTS AND INITIATIVES. THE NEW WEBSITE MERGES THE TGEN AND TGEN FOUNDATION WEBSITES INTO ONE, WHICH MAKES IT EASIER TO LEARN ABOUT AND SUPPORT THE MISSION OF TGEN. OUR NEW IDENTITY RETAINS THE QUALITIES OF OUR BRAND PROMISE BUT REFLECTS OUR EVOLUTION OVER THE PAST DECADE IN BECOMING LEADERS IN THE AREA OF PERSONALIZED MEDICINE. THE NEW TGEN WEBSITE ALSO INCORPORATES THE USE OF RESPONSIVE DESIGN, AN INNOVATIVE LAYOUT DESIGN THAT ALLOWS THE WEBSITE TO BE PROPERLY RENDERED ON ALL DEVICE TYPES, SO THAT VISITORS TO THE SITE ARE ENSURED A POSITIVE BROWSING EXPERIENCE FROM BOTH AN AESTHETIC AS WELL AS A NAVIGATIONAL PERSPECTIVE.
CONSOLIDATED AUDITED FINANCIAL STATEMENTS	FORM 990, PART IV, LINE 12B	CONSOLIDATED AUDITED FINANCIAL STATEMENTS WERE ISSUED FOR THE 13-MONTH PERIOD ENDING DECEMBER 31, 2012. THE TAX YEAR BEING REPORTED FOR THIS FORM 990 IS FOR THE YEAR ENDED NOVEMBER 30, 2012. BUSINESS AND FAMILY RELATIONSHIPS FORM 990, PART VI, LINE 2 DANIEL VON HOFF AND EDWARD SUH HAVE A BUSINESS RELATIONSHIP. JEFFREY TRENT, DANIEL VON HOFF AND EDWARD SUH HAVE A BUSINESS RELATIONSHIP. ROBERT BULLA AND WILLIAM POST HAVE A BUSINESS RELATIONSHIP.
DESCRIPTION OF SIGNIFICANT CHANGES TO ORGANIZING OR ENABLING DOCUMENT	FORM 990, PART VI, LINE 4	THE BYLAWS WERE AMENDED EFFECTIVE MARCH 12, 2012 TO REFLECT THE TERMINATION OF THE AFFILIATION AGREEMENT WITH VAN ANDEL RESEARCH INSTITUTE (VARI) WHEREBY VARI IS NO LONGER THE SOLE MEMBER OF TGEN AND TGEN CONVERTED FROM A MEMBER-BASED TO A DIRECTOR-BASED ARIZONA NONPROFIT CORPORATION. GOVERNANCE STRUCTURE FORM 990, PART VI, LINES 6, 7A & 7B LINE 6 THROUGH MARCH 12, 2012 THE SOLE MEMBER OF TGEN WAS VAN ANDEL RESEARCH INSTITUTE, A MICHIGAN CHARITABLE TRUST. EFFECTIVE MARCH 12, 2012, TGEN AND VARI AGREED TO TERMINATE THEIR AFFILIATION AGREEMENT, AND TGEN CONVERTED FROM A MEMBER-BASED, ARIZONA NONPROFIT CORPORATION TO A DIRECTOR-BASED, ARIZONA NONPROFIT CORPORATION, WHEREBY VARI IS NO LONGER THE SOLE MEMBER OF TGEN. LINE 7A VAN ANDEL RESEARCH INSTITUTE, AS THE SOLE MEMBER OF TGEN THROUGH 3/12/12, APPOINTED ELECTED DIRECTORS TO TGEN'S BOARD OF DIRECTORS FROM A LIST OF INDIVIDUALS PRESENTED BY THE NOMINATING COMMITTEE. EFFECTIVE 3/12/12 THE BOARD OF DIRECTORS OF TGEN HAS THE AUTHORITY TO ELECT AND APPOINT DIRECTORS AS NOMINATED BY THE BOARD OF GOVERNANCE AND EXECUTIVE COMPENSATION COMMITTEE. LINE 7B VAN ANDEL RESEARCH INSTITUTE, AS THE SOLE MEMBER OF TGEN THROUGH 3/12/12, RETAINED CERTAIN APPROVAL RIGHTS AS OUTLINED IN THE BYLAWS. EFFECTIVE 3/12/12, ALL GOVERNANCE DECISIONS ARE MADE BY THE BOARD OF DIRECTORS OF TGEN.
PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW 990	FORM 990, PART VI, LINE 11	THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE FINANCE DEPARTMENT. THE 990 IS THEN REVIEWED BY THE FINANCE DEPARTMENT AND OTHER MEMBERS OF MANAGEMENT. THE FORM 990 IS POSTED ON THE BOARD WEBSITE PRIOR TO FILING WITH THE IRS.
PROCESS USED TO MONITOR TRANSACTIONS FOR CONFLICTS OF INTEREST	FORM 990, PART VI, LINE 12C	TGEN ISSUES A CONFLICT OF INTEREST QUESTIONNAIRE ON AN ANNUAL BASIS TO ALL DIRECTOR LEVEL POSITIONS AND ABOVE IN ADDITION TO ANY KEY EMPLOYEES DESIGNATED BY THE CHIEF OPERATING OFFICER. THE QUESTIONNAIRES ARE REVIEWED BY THE CHIEF FINANCIAL OFFICER, AND THOSE EMPLOYEES WITH CONFLICTS ARE SENT FOR FURTHER REVIEW TO CHIEF OPERATING OFFICER TO ENSURE A PLAN IS SET FORTH. UPDATES TO THE LIST ARE HANDLED ON AN AS NEEDED BASIS BASED ON CONTRACT REVIEWS AND EMPLOYEE INFORMATION.
PROCESS USED TO DETERMINE COMPENSATION	FORM 990, PART VI, LINES 15A AND 15B	TGEN'S GOVERNANCE AND EXECUTIVE COMPENSATION COMMITTEE WILL ACT IN AN "ADVICE AND CONSENT" CAPACITY REVIEWING THE RECOMMENDATIONS FOR THE PRESIDENT AND SCIENTIFIC DIRECTOR REGARDING THE COMPENSATION OF DISQUALIFIED PERSON AND FORWARDING FINAL RECOMMENDATIONS TO THE FULL BOARD FOR APPROVAL. DISQUALIFIED PERSONS (EXCEPT FOR THE PRESIDENT AND SCIENTIFIC DIRECTOR) WILL NOT BE PRESENT FOR, OR PARTICIPATE IN, COMMITTEE DELIBERATIONS CONCERNING THEIR COMPENSATION (OTHER THAN TO ANSWER QUESTIONS). THE PRESIDENT AND SCIENTIFIC DIRECTOR WILL PARTICIPATE IN THE DELIBERATIONS CONCERNING THE COMPENSATION OF DIRECT REPORTS. DURING THE DECISION MAKING PROCESS, THE COMMITTEE WILL ADHERE TO THE EXECUTIVE COMPENSATION PHILOSOPHY. THE COMMITTEE IS AUTHORIZED (AND PROVIDED WITH SUFFICIENT FUNDING) TO ANNUALLY ENGAGE OUTSIDE INDEPENDENT COMPENSATION AND LEGAL ADVISORS, WHEN DEEMED NECESSARY AND ADVISABLE. THE COMMITTEE WILL COMPLY WITH THE "REBUTTABLE PRESUMPTION OF REASONABLENESS" UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE WHENEVER POSSIBLE. THE COMMITTEE WILL REVIEW AND UNDERSTAND THE INTERNAL REVENUE CODE PROVISIONS DEALING WITH "EXCESS BENEFIT TRANSACTIONS CONCERNING DISQUALIFIED PERSONS' COMPENSATION". WHEN DEVELOPING A COMPENSATION PHILOSOPHY TGEN KEPT IN MIND THE FOLLOWING FACTORS: THE TGEN MISSION AND STRATEGY THE TGEN CULTURE TRENDS IN COMPENSATION IN THE EXTERNAL ENVIRONMENT TRENDS IN RECRUITMENT OF NEW EMPLOYEES TRENDS IN ORGANIZATIONAL EMPLOYEE TURNOVER TGEN'S LIFE CYCLE STAGE
AVAILABILITY OF GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY,	AND FINANCIAL STATEMENTS TO THE GENERAL PUBLIC	FORM 990, PART VI, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED TO THE GENERAL PUBLIC UPON REQUEST.
BOARD OF GOVERNORS	PART VII, SECTION A, LINE 1A	TGEN HAS A BOARD OF GOVERNORS THAT IS COMPRISED OF CURRENT VOTING DIRECTORS AND SOME FORMER DIRECTORS THAT REMAIN AFFILIATED WITH TGEN IN AN ADVISORY ROLE. THE CURRENT GOVERNORS NOT LISTED AS DIRECTORS IN PART VII INCLUDE: BETSEY BAYLESS; RICHARD BOALS; SUSAN CLARK-JOHNSON; THE HONORABLE DIANE ENOS; JOHN HAEGER, PHD; THE HONORABLE JIM SLATTERY; DR. VICTOR TRASTEK; RAYMOND DUBOIS, MD, PHD; ANN WEAVER HART, PHD.
HOURS DEVOTED TO RELATED ORGANIZATION	FORM 990, PART VII	THE FOLLOWING INDIVIDUALS REPORTED IN PART VII ALSO DEVOTE TIME TO THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION (FOUNDATION), A RELATED TAX-EXEMPT ORGANIZATION AS INDICATED: JEFFREY TRENT (39 HOURS PER WEEK TGEN; 1 HOUR PER WEEK FOUNDATION) TERESA BURLESON (39 HOURS PER WEEK TGEN; 1 HOUR PER WEEK FOUNDATION). DAVID VAN ANDEL AND JOHN KENNEDY ARE BOTH TGEN DIRECTORS WHO ARE COMPENSATED BY VARI, A RELATED TAX-EXEMPT ORGANIZATION; VAN ANDEL AS A CHAIRMAN/CEO AND KENNEDY AS A TRUSTEE. COMPENSATION AND HOURS INFORMATION WAS NOT AVAILABLE FOR DISCLOSURE ON THIS RETURN.
OTHER CHANGES IN NET ASSETS OR FUND BALANCES	PART XI, LINE 5	UNREALIZED GAIN/LOSSES $658,933

Schedule R IRS990ScheduleR

Form990 Schedule R Part I Form990ScheduleRPartI (5 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EINEIN	Primary ActivitiesPrimaryActivities	Legal Domicile StateLegalDomicileState	Total IncomeTotalIncome	EOY AssetsEOYAssets	Business Name Line1DirectControllingEntityName/BusinessNameLine1
TGEN ACCELERATOR MANAGEMENT LLC
445 NORTH 5TH STREET 600	PHOENIX	AZ	85004	753065445	GENOMICS	AZ	0	0	NA
THE CENTER FOR TRANSLATIONAL DRUG DEV
445 NORTH 5TH STREET 600	PHOENIX	AZ	85004	432047329	DRUG DEVEL.	AZ	3713086	3089363	TGEN ACC MGT
INT'L BIOSCIENCES COMMERCIALIZATION LLC
445 NORTH 5TH STREET 600	PHOENIX	AZ	85004	272987735	LICENSING	AZ	0	0	TGEN ACC MGT
ASHION ANALYTICS LLC
445 NORTH 5TH STREET 600	PHOENIX	AZ	85004	454587602	GENO ANALYSIS	AZ	0	0	NA
TRANSLATIONAL SYSTEMS LLC
445 NORTH 5TH STREET 600	PHOENIX	AZ	85004	461309498	ADV RESEARCH	AZ	0	0	NA

Form990 Schedule R Part II Form990ScheduleRPartII (2 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EINEIN	Primary ActivitiesPrimaryActivities	Legal Domicile StateLegalDomicileState	Exempt Code SectionExemptCodeSection	Public Charity StatusPublicCharityStatus	Business Name Line1DirectControllingEntityName/BusinessNameLine1	Controlled OrgControlledOrg
TGEN RESEARCH INSTITUTE FOUNDATION
445 NORTH 5TH STREET 600	PHOENIX	AZ	85004	331092191	FUND RAISING	AZ	501(C)(3)	7	TGEN	true
VAN ANDEL RESEARCH INSTITUTE
333 BOSTWICK AVENUE STE 850	GRAND RAPIDS	MI	49503	522000823	MEDICAL RSRCH	MI	501(C)(3)	4	NA	false

Field	Value	IRS element (for citing)
Receipt Of Int Ann Rents Royalties	false	ReceiptOfIntAnnRentsRoyalties
Gift Grant Or Cap Contr To Other Org	false	GiftGrantOrCapContrToOtherOrg
Gift Grant Or Cap Contr Fr Other Org	true	GiftGrantOrCapContrFrOtherOrg
Loans Or Guarantees To Other Org	false	LoansOrGuaranteesToOtherOrg
Loans Or Guarantees From Other Org	false	LoansOrGuaranteesFromOtherOrg
Sale Of Assets To Other Org	false	SaleOfAssetsToOtherOrg
Purchase Of Assets From Other Org	false	PurchaseOfAssetsFromOtherOrg
Exchange Of Assets	false	ExchangeOfAssets
Rental Of Facilities To Other Orgs	false	RentalOfFacilitiesToOtherOrgs
Rental Of Facilities Fr Other Orgs	false	RentalOfFacilitiesFrOtherOrgs
Perform Of Services For Other Orgs	false	PerformOfServicesForOtherOrgs
Perform Of Services By Other Orgs	true	PerformOfServicesByOtherOrgs
Sharing Of Facilities	true	SharingOfFacilities
Sharing Of Paid Employees	true	SharingOfPaidEmployees
Reimbursement Paid To Other Org	true	ReimbursementPaidToOtherOrg
Reimbursement Paid By Other Org	false	ReimbursementPaidByOtherOrg
Other Transfer To Other Org	false	OtherTransferToOtherOrg
Other Transfer From Other Org	false	OtherTransferFromOtherOrg

Transactions Related Orgs Table TransactionsRelatedOrgsTable (5 entries)

Transaction TypeTransactionType	Amount InvolvedAmountInvolved	Method Of Amt DeterminationMethodOfAmtDetermination
THE TRANSLATIONAL GENOMICS RESEARCH INST FDN
L	18008282	ACTUAL COST
THE TRANSLATIONAL GENOMICS RESEARCH INST FDN
M	84000	ACTUAL COST
THE TRANSLATIONAL GENOMICS RESEARCH INST FDN
N	168761	ACTUAL COST
THE TRANSLATIONAL GENOMICS RESEARCH INST FDN
O	3847275	ACTUAL COST
THE TRANSLATIONAL GENOMICS RESEARCH INST FDN
C	6322898	ACTUAL COST